1
|
Debs LH, Vale FL, Walker S, Toro D, Mansouri S, Macomson SD, Rahimi SY. Middle meningeal artery embolization following surgical evacuation of symptomatic chronic subdural hematoma improves outcomes, interim results of a prospective randomized trial. J Clin Neurosci 2024; 128:110783. [PMID: 39137714 DOI: 10.1016/j.jocn.2024.110783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2024] [Revised: 07/29/2024] [Accepted: 08/10/2024] [Indexed: 08/15/2024]
Abstract
BACKGROUND Outcomes after surgical treatment of chronic subdural hematoma (cSDH) remain undesirable in a significant proportion of patients. We aimed to show the role of middle meningeal artery (MMA) embolization and to demonstrate its benefits. METHODS Thirty-five patients with symptomatic cSDH were enrolled in a prospective randomized trial following evacuation surgery. Participants were randomized to embolization or control group (expectant management following surgical evacuation without embolization). Patients were followed throughout their hospitalization and outpatient follow-ups. The main goals of this planned interim analysis were to assess neurological outcome and resource utilization. RESULTS The groups were comparable in terms of sex, age and follow-up retention rates. Side(s) of intervention(s) and hematoma size were similar. There was no statistical difference in neurological examination improvement at discharge, but at follow-up, we observed a decline in neurologic exam in the control group (p = 0.03). Control group participants required more re-interventions (p = 0.02) and were followed in clinic and during related readmissions for longer (p = 0.02). The number of imaging studies obtained in relation to the disease management was higher in the control group (p = 0.01). CONCLUSIONS Our results suggest a beneficial role for the addition of MMA embolization to surgical intervention in the treatment of symptomatic chronic subdural hematoma. Neurological outcomes were significantly better in the embolization group. This contributed to less need for follow-up, re-interventions, and imaging studies.
Collapse
Affiliation(s)
- Luca H Debs
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA.
| | - Fernando L Vale
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA
| | - Samantha Walker
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA
| | - Diana Toro
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA
| | - Seena Mansouri
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA
| | - Samuel D Macomson
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA
| | - Scott Y Rahimi
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA
| |
Collapse
|
2
|
Imai N, Kato T, Ito Y, Morishima R, Aki T, Shirakami SI. Timing of chronic subdural hematoma treatment affects middle meningeal artery embolization outcome. Surg Neurol Int 2024; 15:214. [PMID: 38974558 PMCID: PMC11225511 DOI: 10.25259/sni_293_2024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2024] [Accepted: 06/04/2024] [Indexed: 07/09/2024] Open
Abstract
Background Chronic subdural hematoma (CSDH) is a condition that tends to recur frequently. Although middle meningeal artery embolization (MMAE) is an effective CSDH treatment, there is currently no consensus regarding the optimal timing for embolization. Methods In this single-center and retrospective study, we reviewed 72 cases with 1st-time recurrent CSDH from January 2018 to July 2023 and identified those treated with MMAE to examine its effect and the impact of differences in the timing of treatment. Results Of the 72 cases with CSDH recurrence for the 1st time (mean age: 80.4 ± 9.7 years; men: 62 [86.1%]; mean first recurrence interval: 33 ± 24 days), 27 (37.5%) experienced a second recurrence. The mean first recurrence interval was shorter in cases with a second recurrence compared to cured cases: 24.3 ± 18.6 versus 38.3 ± 25.6 days, respectively (P = 0.005). MMAE was performed in 17 (23.6%) cases (mean age: 82 ± 6.2 years; men: 14 [82.4%]). The mean time from initial surgical treatment to embolization was 52.4 ± 35.4 days, and the mean recurrence interval before MMAE was 24.9 ± 19.6 days. Six cases (35.3%) experienced post-embolization recurrence and required surgical treatment. The mean recurrence interval before MMAE was shorter in cases with recurrence after MMAE (15 ± 6.4 vs. 30 ± 22.1 days, P = 0.023). The time from initial surgical treatment to embolization was significantly shorter: 31.3 ± 12.8 versus 63.9 ± 38.9 days (P = 0.039). Conclusion Cases with a short first recurrence interval were more likely to experience a second recurrence. Repeated recurrences within a short time increased the likelihood of post-embolization recurrence. MMAE performed early following the initial surgical treatment increased the recurrence risk.
Collapse
Affiliation(s)
- Naoya Imai
- Department of Neurosurgery, Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Minokamo, Japan
| | - Takayuki Kato
- Department of Neurosurgery, Daiyukai General Hospital, Ichinomiya, Japan
| | - Yohei Ito
- Department of Neurosurgery, National Hospital Organization Toyohashi Medical Center, Toyohashi, Japan
| | - Ryo Morishima
- Department of Neurosurgery, Daiyukai General Hospital, Ichinomiya, Japan
| | - Tatsuki Aki
- Department of Neurosurgery, Daiyukai General Hospital, Ichinomiya, Japan
| | | |
Collapse
|
3
|
Salah WK, Findlay MC, Baker CM, Scoville JP, Bounajem MT, Ogilvy CS, Moore JM, Riina HA, Levy EI, Siddiqui AH, Spiotta AM, Cawley CM, Khalessi AA, Tanweer O, Hanel R, Gross BA, Kuybu O, Howard BM, Hoang AN, Baig AA, Khorasanizadeh M, Mendez Ruiz AA, Cortez G, Davies JM, Lang MJ, Thomas AJ, Tonetti DA, Khalife J, Sioutas GS, Carroll K, Abecassis ZA, Jankowitz BT, Ruiz Rodriguez J, Levitt MR, Kan PT, Burkhardt JK, Srinivasan V, Salem MM, Grandhi R. The Influence of Coagulopathy on Radiographic and Clinical Outcomes in Patients Undergoing Middle Meningeal Artery Embolization as Standalone Treatment for Non-acute Subdural Hematomas. J Neurotrauma 2024; 41:1375-1383. [PMID: 38481125 DOI: 10.1089/neu.2023.0413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/11/2024] Open
Abstract
Middle meningeal artery embolization (MMAE) is emerging as a safe and effective standalone intervention for non-acute subdural hematomas (NASHs); however, the risk of hematoma recurrence after MMAE in coagulopathic patients is unclear. To characterize the impact of coagulopathy on treatment outcomes, we analyzed a multi-institutional database of patients who underwent standalone MMAE as treatment for NASH. We classified 537 patients who underwent MMAE as a standalone intervention between 2019 and 2023 by coagulopathy status. Coagulopathy was defined as use of anticoagulation/antiplatelet agents or pre-operative thrombocytopenia (platelets <100,000/μL). Demographics, pre-procedural characteristics, in-hospital course, and patient outcomes were collected. Thrombocytopenia, aspirin use, antiplatelet agent use, and anticoagulant use were assessed using univariate and multivariate analyses to identify any characteristics associated with the need for rescue surgical intervention, mortality, adverse events, and modified Rankin Scale score at 90-day follow-up. Propensity score-matched cohorts by coagulopathy status with matching covariates adjusting for risk factors implicated in surgical recurrence were evaluated by univariate and multivariate analyses. Minimal differences in pre-operative characteristics between patients with and those without coagulopathy were observed. On unmatched and matched analyses, patients with coagulopathy had higher rates of requiring subsequent surgery than those without (unmatched: 9.9% vs. 4.3%; matched: 12.6% vs. 4.6%; both p < 0.05). On matched multivariable analysis, patients with coagulopathy had an increased odds ratio (OR) of requiring surgical rescue (OR 3.95; 95% confidence interval [CI] 1.68-9.30; p < 0.01). Antiplatelet agent use (ticagrelor, prasugrel, or clopidogrel) was also predictive of surgical rescue (OR 4.38; 95% CI 1.51-12.72; p = 0.01), and patients with thrombocytopenia had significantly increased odds of in-hospital mortality (OR 5.16; 95% CI 2.38-11.20; p < 0.01). There were no differences in follow-up radiographic and other clinical outcomes in patients with and those without coagulopathy. Patients with coagulopathy undergoing standalone MMAE for treatment of NASH may have greater risk of requiring surgical rescue (particularly in patients using antiplatelet agents), and in-hospital mortality (in thrombocytopenic patients).
Collapse
Affiliation(s)
- Walid K Salah
- Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA
- School of Medicine, University of Utah, Salt Lake City, Utah, USA
| | | | - Cordell M Baker
- Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA
| | - Jonathan P Scoville
- Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA
| | - Michael T Bounajem
- Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA
| | - Christopher S Ogilvy
- Department of Neurological Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Justin M Moore
- Department of Neurological Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Howard A Riina
- Department of Neurosurgery, NYU Langone Health, New York, New York, USA
| | - Elad I Levy
- Department of Neurosurgery, University at Buffalo, Buffalo, New York, USA
| | - Adnan H Siddiqui
- Department of Neurosurgery, University at Buffalo, Buffalo, New York, USA
| | - Alejandro M Spiotta
- Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - C Michael Cawley
- Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Alexander A Khalessi
- Department of Neurological Surgery, University of California San Diego, La Jolla, California, USA
| | - Omar Tanweer
- Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
| | - Ricardo Hanel
- Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA
| | - Bradley A Gross
- Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Okkes Kuybu
- Department of Neurosurgery, Penn Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Brian M Howard
- Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Alex N Hoang
- Department of Neurosurgery, Houston Methodist, Houston, Texas, USA
| | - Ammad A Baig
- Department of Neurosurgery, University at Buffalo, Buffalo, New York, USA
| | | | - Aldo A Mendez Ruiz
- Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Gustavo Cortez
- Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA
| | - Jason M Davies
- Department of Neurosurgery, University at Buffalo, Buffalo, New York, USA
| | - Michael J Lang
- Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Ajith J Thomas
- Department of Neurosurgery, Cooper University Healthcare, Camden, New Jersey, USA
| | - Daniel A Tonetti
- Department of Neurosurgery, Cooper University Healthcare, Camden, New Jersey, USA
| | - Jane Khalife
- Department of Neurosurgery, Cooper University Healthcare, Camden, New Jersey, USA
| | - Georgios S Sioutas
- Department of Neurosurgery, Penn Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Kate Carroll
- Department of Neurological Surgery, University of Washington, Seattle, Washington, USA
| | - Zachary A Abecassis
- Department of Neurological Surgery, University of Washington, Seattle, Washington, USA
| | - Brian T Jankowitz
- Department of Neurosurgery, Penn Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Juan Ruiz Rodriguez
- Department of Neurological Surgery, University of Washington, Seattle, Washington, USA
| | - Michael R Levitt
- Department of Neurological Surgery, University of Washington, Seattle, Washington, USA
| | - Peter T Kan
- Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
| | - Jan-Karl Burkhardt
- Department of Neurosurgery, Penn Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Visish Srinivasan
- Department of Neurosurgery, Penn Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Mohamed M Salem
- Department of Neurosurgery, Penn Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Ramesh Grandhi
- Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA
| |
Collapse
|
4
|
Flood R, Nunn AC, Talbott J, Cox A, Minks D, Wareham J, Crossley R, Malcolm G, Patel NK, Wigfield C, Williams A, Mortimer A. Initial experience using middle meningeal artery embolisation for patients with recurrent and high-recurrence-risk chronic subdural haematoma. J Clin Neurosci 2024; 125:126-131. [PMID: 38788605 DOI: 10.1016/j.jocn.2024.05.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 05/02/2024] [Accepted: 05/19/2024] [Indexed: 05/26/2024]
Abstract
Recurrence rates following surgical management of chronic subdural haematoma (CSDH) range from 5 to 33 %. There is growing evidence which suggests middle meningeal artery embolisation (MMAe) may reduce recurrence rates when used as surgical adjunct or standalone treatment. In this study we described our experience of this new procedure in the our UK institution. Patients with recurrent CSDH or CSDH at high risk of recurrence were selected for MMAe on a case-by-case basis following MDT discussion. A departmental database was used to identify patients treated. 26 CSDH were embolised in 20 patients; 9 CSDH were de-novo and 17 were recurrent. 10/26 CSDH were treated with MMAe only. No procedural mortality, access site or thrombo-embolic complications occurred. One patient experienced symptomatic collection growth 12 h following MMAe and required surgical drainage. 15 (75 %) of patients were living at home at follow-up (mean 14 months). On imaging follow-up 15/18 showed CSDH volume reduction or resolution, 1/18 remained stable requiring no further treatment, 2/18 patients suffered recurrent CSDH requiring treatment. In both recurrent cases incomplete embolisation was noted on procedural imaging (posterior division of MMA not embolised). Persistent posterior MMA division filling was significantly associated with collection recurrence (p = 0.002). Our results suggest MMAe as a stand-alone or adjuvant therapy can be performed safely in a UK neuroscience setting and is associated with high rates of symptomatic CSDH size reduction or resolution in problematic CSDH that have either recurred or are prone to recurrence.
Collapse
Affiliation(s)
- R Flood
- Southmead Hospital, North Bristol NHS Trust, United Kingdom.
| | - A C Nunn
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| | - J Talbott
- Blackpool Victoria Hospital, Blackpool Teaching Hospital NHS Foundation Trust, United Kingdom
| | - A Cox
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| | - D Minks
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| | - J Wareham
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| | - R Crossley
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| | - G Malcolm
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| | - N K Patel
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| | - C Wigfield
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| | - A Williams
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| | - A Mortimer
- Southmead Hospital, North Bristol NHS Trust, United Kingdom
| |
Collapse
|
5
|
Debs LH, Walker SE, Rahimi SY. Newer treatment paradigm improves outcomes in the most common neurosurgical disease of the elderly: a literature review of middle meningeal artery embolization for chronic subdural hematoma. GeroScience 2024:10.1007/s11357-024-01173-5. [PMID: 38691299 DOI: 10.1007/s11357-024-01173-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Accepted: 04/23/2024] [Indexed: 05/03/2024] Open
Abstract
Chronic subdural hematoma (cSDH) is one of the most prevalent neurosurgical diseases, especially in the elderly. Yet, its incidence is predicted to increase further, paralleling the growth of the geriatric population. While surgical evacuation is technically straightforward, it is associated with significant morbidity and mortality. In fact, 30% of patients are expected to have hematoma recurrence and to need repeat surgical evacuation, and 20% of patients are expected to lose independence and require long-term care. A pathophysiology more complex than originally presumed explains the disappointing results observed for decades. At its core, the formation of microcapillaries and anastomotic channels with the middle meningeal artery (MMA) perpetuates a constant cycle resulting in persistence of hematoma. The rationale behind MMA embolization is simple: to stop cSDH at its source. Over the last few years, this "newer" option has been heavily studied. It has shown tremendous potential in decreasing hematoma recurrence and improving neurological outcomes. Whether combined with surgical evacuation or performed as the only treatment, the scientific evidence to its benefits is unequivocal. Here, we aimed to review cSDH in the elderly and discuss its more recent treatment options with an emphasis on MMA embolization.
Collapse
Affiliation(s)
- Luca H Debs
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA.
| | - Samantha E Walker
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA
| | - Scott Y Rahimi
- Neurosurgery Department, Medical College of Georgia, Augusta, GA, USA
| |
Collapse
|
6
|
Yohannan B, Martinez Gutierrez JC, Chen PR, Rios A. Middle Meningeal Artery Embolization in Acute Leukemia Patients Presenting With Subdural Hematoma. J Hematol 2024; 13:39-45. [PMID: 38644984 PMCID: PMC11027772 DOI: 10.14740/jh1215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2023] [Accepted: 12/30/2023] [Indexed: 04/23/2024] Open
Abstract
Intracerebral hemorrhage is a potentially fatal complication in patients with acute leukemia and contributing factors include thrombocytopenia and coagulopathy. Patients with acute leukemia may develop subdural hematoma (SDH) spontaneously or secondary to trauma. In patients with acute leukemia and SDH, the surgical evacuation of the hematoma causes significant morbidity and mortality. New approaches and strategies to reduce the need for surgical evacuation are needed to improve outcomes in patients with acute leukemia and intracerebral hemorrhage. We report two cases of acute SDH in patients with acute leukemia successfully treated with middle meningeal artery embolization, a minimally invasive interventional radiology technique, obviating the need for a surgical intervention. The first patient with acute promyelocytic leukemia (APL) presented with coagulopathy and developed an acute SDH after a fall. The second patient with acute myeloid leukemia presented with gum bleeding and also sustained an acute SDH after a fall. Both patients underwent middle meningeal artery embolization for treating their SDHs while actively receiving induction chemotherapy for acute leukemia. Both patients had resolution of their acute SDH and are in remission from their acute leukemia. Middle meningeal artery embolization is a very effective, and within the context of this setting, a novel, minimally invasive technique for management of SDH in acute leukemia patients, which can prevent the need for surgical interventions with its associated comorbidities and high risk of fatal outcomes in patients with acute leukemia and acute SDH.
Collapse
Affiliation(s)
- Binoy Yohannan
- Division of Hematology/Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| | - Juan Carlos Martinez Gutierrez
- Division of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| | - Peng Roc Chen
- Division of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| | - Adan Rios
- Division of Hematology/Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| |
Collapse
|
7
|
Schmolling ÁH, Pérez-García C, Trejo C, López-Frías A, Jaroenngarmsamer T, Rosati S, Arrazola J, Moreu M. Middle Meningeal Artery Embolization for Management of Chronic Subdural Hematoma. Radiographics 2024; 44:e230158. [PMID: 38451847 DOI: 10.1148/rg.230158] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/09/2024]
Abstract
Chronic subdural hematoma (CSDH) is a prevalent medical condition with potentially severe consequences if left untreated. While surgical removal has traditionally been the standard approach for treatment, middle meningeal artery (MMA) embolization has emerged as a promising minimally invasive alternative to reduce recurrences. This comprehensive review provides the general radiology community with an overview of MMA embolization as a therapeutic option for managing CSDH. The authors base their insights on existing evidence and their institutional experience. This overview encompasses the pathophysiology of CSDH as well as the potential advantages and limitations, safety profile, and potential complications of MMA embolization as compared with surgical treatment. The imaging findings seen before and after MMA, as well as insights into the procedural techniques used at the authors' institution, are described. On the basis of reports in the current literature, MMA embolization appears to be a safe and effective therapeutic option for managing CSDH, especially in patients who are unsuitable for surgery or at risk for recurrence. Nonetheless, further research is needed to validate these findings. Results from ongoing clinical trials hold promise for future validation and the establishment of scientific evidence. ©RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material. See the invited commentary by Chatterjee in this issue.
Collapse
Affiliation(s)
- Ángela H Schmolling
- From the Departments of Interventional Neuroradiology (A.H.S., C.P.G., C.T., A.L.F., S.R., M.M.) and Radiology (J.A.), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain; and Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (T.J.)
| | - Carlos Pérez-García
- From the Departments of Interventional Neuroradiology (A.H.S., C.P.G., C.T., A.L.F., S.R., M.M.) and Radiology (J.A.), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain; and Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (T.J.)
| | - Carmen Trejo
- From the Departments of Interventional Neuroradiology (A.H.S., C.P.G., C.T., A.L.F., S.R., M.M.) and Radiology (J.A.), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain; and Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (T.J.)
| | - Alfonso López-Frías
- From the Departments of Interventional Neuroradiology (A.H.S., C.P.G., C.T., A.L.F., S.R., M.M.) and Radiology (J.A.), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain; and Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (T.J.)
| | - Tanaporn Jaroenngarmsamer
- From the Departments of Interventional Neuroradiology (A.H.S., C.P.G., C.T., A.L.F., S.R., M.M.) and Radiology (J.A.), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain; and Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (T.J.)
| | - Santiago Rosati
- From the Departments of Interventional Neuroradiology (A.H.S., C.P.G., C.T., A.L.F., S.R., M.M.) and Radiology (J.A.), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain; and Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (T.J.)
| | - Juan Arrazola
- From the Departments of Interventional Neuroradiology (A.H.S., C.P.G., C.T., A.L.F., S.R., M.M.) and Radiology (J.A.), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain; and Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (T.J.)
| | - Manuel Moreu
- From the Departments of Interventional Neuroradiology (A.H.S., C.P.G., C.T., A.L.F., S.R., M.M.) and Radiology (J.A.), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos s/n, 28040 Madrid, Spain; and Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (T.J.)
| |
Collapse
|
8
|
Niu Y, Zhang Q, Jiang Z, Li W, Chen Z. Middle meningeal artery embolization for the treatment of unilateral large chronic subdural hematoma patients with significant midline shift: A single-center experience. Interv Neuroradiol 2024:15910199241239706. [PMID: 38515352 DOI: 10.1177/15910199241239706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/23/2024] Open
Abstract
BACKGROUND The amount of midline shift (MLS) considered safe for middle meningeal artery embolization (MMAE) in patients with chronic subdural hematoma (CSDH) has not been established. Whether MMAE could be used as upfront treatment for unilateral large CSDH patients with significant MLS (>1 cm) has not been reported. OBJECTIVE To investigate the efficacy and safety of MMAE in unilateral large CSDH patients with MLS > 1 cm. METHODS Eleven carefully selected CSDH patients with mild or moderate symptoms and significant MLS > 1 cm from 1 May 2021 to 31 August 2022 were included in the study. All patients were treated with MMAE using polyvinyl alcohol (PVA) particles. Outcomes were assessed clinically and with interval imaging studies at follow-up. RESULTS All 19 MMAs (unilateral embolization in three patients and bilateral embolization in eight patients) were successfully embolized. All 11 patients were followed for subsequent months, and there was no recurrence and enlargement of CSDH. Procedural adverse events, mortality, or complications were not observed. The average time to achieve a 50% reduction in MLS was approximately four weeks, while it took approximately eight weeks to achieve a 50% reduction in maximal volume. All 11 patients showed improvement in their neurological symptoms at three days post-operation, including four hemiplegic patients. CONCLUSIONS MMAE may demonstrate safety in carefully selected CSDH patients with significant midline shift (MLS > 1 cm), particularly in those who are not suitable for surgery, thus providing a potential alternative approach.
Collapse
Affiliation(s)
- Yin Niu
- Department of Neurosurgery, Third Military Medical University (Army Medical University), Southwest Hospital, Chongqing, China
| | - Qiang Zhang
- Department of Neurosurgery, The 961st Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Qiqihaer, Heilongjiang, China
| | - Zhouyang Jiang
- Department of Neurosurgery, Third Military Medical University (Army Medical University), Southwest Hospital, Chongqing, China
| | - Wenyan Li
- Department of Neurosurgery, Third Military Medical University (Army Medical University), Southwest Hospital, Chongqing, China
| | - Zhi Chen
- Department of Neurosurgery, Third Military Medical University (Army Medical University), Southwest Hospital, Chongqing, China
| |
Collapse
|
9
|
Kim H, Choi Y, Lee Y, Won JK, Lee SH, Suh M, Lee DS, Kang HS, Cho WS, Cheon GJ. Neovascularization in Outer Membrane of Chronic Subdural Hematoma : A Rationale for Middle Meningeal Artery Embolization. J Korean Neurosurg Soc 2024; 67:146-157. [PMID: 38213004 PMCID: PMC10924904 DOI: 10.3340/jkns.2023.0105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Revised: 09/04/2023] [Accepted: 09/25/2023] [Indexed: 01/13/2024] Open
Abstract
OBJECTIVE Chronic subdural hematomas (cSDHs) are generally known to result from traumatic tears of bridging veins. However, the causes of repeat spontaneous cSDHs are still unclear. We investigated the changes in vasculature in the human dura mater and outer membrane (OM) of cSDHs to elucidate the cause of their spontaneous repetition. METHODS The dura mater was obtained from a normal control participant and a patient with repeat spontaneous cSDHs. The pathological samples from the patient included the dura mater and OM tightly adhered to the inner dura. The samples were analyzed with a particular focus on blood and lymphatic vessels by immunohistochemistry, 3-dimensional imaging using a transparent tissue clearing technique, and electron microscopy. RESULTS The dural border cell (DBC) layer of the dura mater and OM were histologically indistinguishable. There were 5.9 times more blood vessels per unit volume of tissue in the DBC layer and OM in the patient than in the normal control. The DBC layer and OM contained pathological sinusoidal capillaries not observed in the normal tissue; these capillaries were connected to the middle meningeal arteries via penetrating arteries. In addition, marked lymphangiogenesis in the periosteal and meningeal layers was observed in the patient with cSDHs. CONCLUSION Neovascularization in the OM seemed to originate from the DBC layer; this is a potential cause of repeat spontaneous cSDHs. Embolization of the meningeal arteries to interrupt the blood supply to pathological capillaries via penetrating arteries may be an effective treatment option.
Collapse
Affiliation(s)
- Hyun Kim
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine or College of Pharmacy, Seoul National University, Seoul, Korea
- Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - Yoori Choi
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine or College of Pharmacy, Seoul National University, Seoul, Korea
- Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - Youngsun Lee
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine or College of Pharmacy, Seoul National University, Seoul, Korea
- Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - Jae-Kyung Won
- Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - Sung Ho Lee
- Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - Minseok Suh
- Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - Dong Soo Lee
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, College of Medicine or College of Pharmacy, Seoul National University, Seoul, Korea
- Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - Hyun-Seung Kang
- Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - Won-Sang Cho
- Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
| | - Gi Jeong Cheon
- Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
- Radiation Medicine Institute, Seoul National University College of Medicine, Seoul, Korea
- Institute on Aging, Seoul National University, Seoul, Korea
| |
Collapse
|
10
|
Ellens NR, Schartz D, Kohli G, Rahmani R, Akkipeddi SMK, Mattingly TK, Bhalla T, Bender MT. Safety and efficacy comparison of embolic agents for middle meningeal artery embolization for chronic subdural hematoma. J Cerebrovasc Endovasc Neurosurg 2024; 26:11-22. [PMID: 37828746 PMCID: PMC10995466 DOI: 10.7461/jcen.2023.e2023.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 07/26/2023] [Accepted: 08/03/2023] [Indexed: 10/14/2023] Open
Abstract
OBJECTIVE To perform a systematic review and meta-analysis evaluating the efficacy of middle meningeal artery embolization in terms of both clinical and radiographic outcomes, when performed with different embolic agents. METHODS A systematic literature review and meta-analysis was performed to evaluate the impact of embolic agents on outcomes for middle meningeal artery (MMA) embolization. The use of polyvinyl alcohol (PVA) with or without (±) coils, N-butyl cyanoacrylate (n-BCA) ± coils, and Onyx alone were separately evaluated. Primary outcome measures were recurrence, the need for surgical rescue and in-hospital periprocedural complications. RESULTS Thirty-one studies were identified with a total of 1,134 patients, with 786 receiving PVA, 167 receiving n-BCA, and 181 patients receiving Onyx. There was no difference in the recurrence rate (5.5% for PVA, 4.5% for n-BCA, and 6.5% for Onyx, with P=0.71) or need for surgical rescue (5.0% for PVA, 4.0% for n-BCA, and 6.9% for Onyx, with P=0.89) based on the embolic agent. Procedural complications also did not differ between embolic agents (1.8% for PVA, 3.6% for n-BCA, and 1.6% for Onyx, with P=0.48). CONCLUSIONS Rates of recurrence, need for surgical rescue, and periprocedural complication following MMA embolization are not impacted by the type of embolic agent utilized. Ongoing clinical trials may be used to further investigate these findings.
Collapse
Affiliation(s)
- Nathaniel R. Ellens
- Department of Neurosurgery, University of Rochester Medical Center, New York, USA
| | - Derrek Schartz
- Department of Imaging Sciences, University of Rochester Medical Center, New York, USA
| | - Gurkirat Kohli
- Department of Neurosurgery, University of Rochester Medical Center, New York, USA
| | - Redi Rahmani
- Department of Neurosurgery, University of Rochester Medical Center, New York, USA
| | | | - Thomas K. Mattingly
- Department of Neurosurgery, University of Rochester Medical Center, New York, USA
| | - Tarun Bhalla
- Department of Neurosurgery, University of Rochester Medical Center, New York, USA
| | - Matthew T. Bender
- Department of Neurosurgery, University of Rochester Medical Center, New York, USA
| |
Collapse
|
11
|
Palmer B, Campbell M, Maertz K, Narigon L, Herzing K, Santry H, Boyce W, Narayanan R, Patel A. Analysis of middle meningeal artery embolization for the treatment of chronic, acute on chronic, and subacute subdural hematomas. Surg Neurol Int 2024; 15:71. [PMID: 38468652 PMCID: PMC10927174 DOI: 10.25259/sni_607_2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Accepted: 02/07/2024] [Indexed: 03/13/2024] Open
Abstract
Background Chronic subdural hematoma (cSDH) is a common sequela of traumatic brain injury. Middle meningeal artery embolization (MMAE) has shown promising results as an emerging minimally invasive alternative treatment. The purpose of this study is to examine the safety and efficacy of MMAE performed in patients with cSDH, acute-on-chronic, and subacute SDH with a traumatic etiology. Methods This retrospective study included cases performed at a Level II Trauma Center between January 2019 and December 2020 for MMAE of cSDHs. Data collected included patient demographic characteristics and comorbidities, SDH characteristics, complications, and efficacy outcomes. The lesion measurements were collected before the procedure, 4-6 weeks and 3-6 months post-procedure. Results In our patient population, 78% (39) either had lesions improve or completely resolved. The sample included 50 patients with a mean age of 74 years old. Statistically significant reductions in lesion size were found from pre- to post-procedure in the left lesions, right lesions, and midline shifts. The left lesions decreased from 13.88 ± 5.70 mm to 3.19 ± 4.89 mm at 3-6 months with P < 0.001. The right lesions decreased from 13.74 ± 5.28 mm to 4.93 ± 7.46 mm at 3-6 months with P = 0.02. Midline shifts decreased from 3.78 ± 3.98 mm to 0.48 ± 1.31 mm at 3-6 months with P = 0.02. No complications were experienced for bleeding, hematoma, worsening SDH, pseudoaneurysm, or stroke. Conclusion Our pilot study from a single center utilizing MMAE demonstrates that MMAE is successful without increasing treatment-related complications not only for cSDH but also in acute-on-cSDH and SDH with a subacute component.
Collapse
Affiliation(s)
- Brandi Palmer
- Department of Trauma and Acute Care Surgery, Kettering Health Main Campus, Kettering, Ohio, United States
| | - Melody Campbell
- Department of Trauma and Acute Care Surgery, Kettering Health Main Campus, Kettering, Ohio, United States
| | - Kellie Maertz
- Department of Trauma and Acute Care Surgery, Kettering Health Main Campus, Kettering, Ohio, United States
| | - Laurie Narigon
- Department of Trauma and Acute Care Surgery, Kettering Health Main Campus, Kettering, Ohio, United States
| | - Karen Herzing
- Department of Trauma and Acute Care Surgery, Kettering Health Main Campus, Kettering, Ohio, United States
| | - Heena Santry
- Department of Trauma and Acute Care Surgery, Kettering Health Main Campus, Kettering, Ohio, United States
| | - William Boyce
- Department of Radiology, Kettering Health Main Campus, Kettering, Ohio, United States
| | - Ragavan Narayanan
- Department of Trauma and Acute Care Surgery, Kettering Health Main Campus, Kettering, Ohio, United States
| | - Akil Patel
- Department of Kettering Brain and Spine, Kettering Health Main Campus, Kettering, Ohio, United States
| |
Collapse
|
12
|
Doron O, Patel AB, Hawryluk GWJ. Neurovascular Interventions for Neurotrauma: From Treatment of Injured Vessels to Treatment of the Injured Brain? Oper Neurosurg (Hagerstown) 2024; 26:247-255. [PMID: 37976141 DOI: 10.1227/ons.0000000000000980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 09/17/2023] [Indexed: 11/19/2023] Open
Abstract
Traumatic brain injury is often associated with a direct or secondary neurovascular pathology. In this review, we present recent advancements in endovascular neurosurgery that enable accurate and effective vessel reconstruction with emphasis on its role in early diagnosis, the expanding use of flow diversion in pseudoaneurysms, and traumatic arteriovenous fistulas. In addition, future directions in which catheter-based interventions could potentially affect traumatic brain injury are described: targeting blood brain barrier integrity using the advantages of intra-arterial drug delivery of blood brain barrier stabilizers to prevent secondary brain edema, exploring the impact of endovascular venous access as a means to modulate venous outflow in an attempt to reduce intracranial pressure and augment brain perfusion, applying selective intra-arterial hypothermia as a neuroprotection method mitigating some of the risks conferred by systemic cooling, trans-vessel wall delivery of regenerative therapy agents, and shifting attention using multimodal neuromonitoring to post-traumatic vasospasm to further characterize the role it plays in secondary brain injury. Thus, we believe that the potential of endovascular tools can be expanded because they enable access to the "highways" governing perfusion and flow and call for further research focused on exploring these routes because it may contribute to novel endovascular approaches currently used for treating injured vessels, harnessing them for treatment of the injured brain.
Collapse
Affiliation(s)
- Omer Doron
- Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston , Massachusetts , USA
- Department of Biomedical Engineering, The Aldar and Iby Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv , Israel
| | - Aman B Patel
- Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston , Massachusetts , USA
| | - Gregory W J Hawryluk
- Department of Neurosurgery, Akron General Neuroscience Institute, Cleveland Clinic, Akron , Ohio , USA
| |
Collapse
|
13
|
Abdollahifard S, Farrokhi A, Yousefi O, Valibeygi A, Azami P, Mowla A. Particle embolic agents for embolization of middle meningeal artery in the treatment of chronic subdural hematoma: A systematic review and meta-analysis. Interv Neuroradiol 2024; 30:94-104. [PMID: 36112765 PMCID: PMC10956449 DOI: 10.1177/15910199221125977] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Accepted: 08/25/2022] [Indexed: 02/18/2024] Open
Abstract
OBJECTIVE In this systematic review and meta-analysis, we investigated the efficacy and safety of middle meningeal artery embolization (MMAE) using particle embolic agents to treat cSDH. METHODS To retrieve articles investigating outcomes of patients following MMAE with particle agents and to compare their outcome with conventional treatment, Scopus, PubMed, Embase, and Web of Science were searched using relevant keywords. Original articles with more than 10 cases were included. The meta-analysis was carried out using the R studio and the random-effects model. Publication bias was assessed using Peter's test and quality assessment using NIH tools. RESULTS Eleven studies with 359 patients were included. The analysis revealed a pooled recurrence rate of 5% (CI: 3-8%), a need for reoperation rate of 5% (3-9%), and a peri-procedural complication rate of 4% (CI:2-9%) following MMAE with particle embolic agents. The pooled rates of decrease in size or resolution of the hematoma were 85% (CI:66-94%) and 66% (39-86%), respectively. Comparing MMAE using particulate embolysate with conventional treatments, risk ratio (RR) of 0.10 (CI:0.04-0.27) was achieved for recurrence, 0.25(CI:0.13-0.49) for reoperation, and 0.34 (CI:0.16-0.27) for peri-procedural complications. 91% of cSDH cases responded to MMAE with particles in the way they showed either down-sizing or complete resolution of the hematoma on follow-up imaging. In comparison, this rate was found to be 63% following conventional treatment. CONCLUSION Middle meningeal artery embolization using particle embolysates is a safe and effective technique for the treatment of cSDH, whether as a standalone intervention or in combination with conventional treatments.
Collapse
Affiliation(s)
- Saeed Abdollahifard
- Student research committee, Shiraz University of Medical Sciences, Shiraz, Iran
- Research center for neuromodulation and pain, Shiraz, Iran
| | - Amirmohammad Farrokhi
- Student research committee, Shiraz University of Medical Sciences, Shiraz, Iran
- Research center for neuromodulation and pain, Shiraz, Iran
| | - Omid Yousefi
- Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Adib Valibeygi
- Fasa Neuroscience Circle (FNC), Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
| | - Pouria Azami
- Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Ashkan Mowla
- Division of Stroke and Endovascular Neurosurgery, Department of Neurological Surgery, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA
| |
Collapse
|
14
|
Lara-Reyna J, Morgan IC, Odland IC, Carrasquilla A, Matsoukas S, Mocco J, Bederson JB, Kellner CP, Rapoport BI. Endoscope-Assisted Evacuation of Subdural Hematoma and Middle Meningeal Artery Embolization in a Single Session in the Angiography Suite: 2-Dimensional Operative Video. Oper Neurosurg (Hagerstown) 2024; 26:115-116. [PMID: 37861319 PMCID: PMC10688771 DOI: 10.1227/ons.0000000000000919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Accepted: 07/17/2023] [Indexed: 10/21/2023] Open
Affiliation(s)
- Jacques Lara-Reyna
- Department of Neurosurgery, University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA
| | - Isabella C. Morgan
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Mount Sinai BioDesign, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Ian C. Odland
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Mount Sinai BioDesign, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Alejandro Carrasquilla
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Stavros Matsoukas
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - J Mocco
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Joshua B. Bederson
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Mount Sinai BioDesign, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Christopher P. Kellner
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Benjamin I. Rapoport
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Mount Sinai BioDesign, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| |
Collapse
|
15
|
Sila D, Casnati FL, Vojtková M, Kirsch P, Rath S, Charvát F. Middle Meningeal Artery Embolization versus Surgery in Patients with Chronic Subdural Hematoma-No More Fence Sitting? Neurol Int 2023; 15:1480-1488. [PMID: 38132975 PMCID: PMC10745991 DOI: 10.3390/neurolint15040096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 11/23/2023] [Accepted: 12/02/2023] [Indexed: 12/23/2023] Open
Abstract
BACKGROUND Endovascular treatment of patients with chronic subdural hematoma using middle meningeal artery (MMA) embolization could become an alternative to surgical hematoma evacuation. The aim of the study was to compare methods and identify parameters to help determine the correct treatment modality. METHODS We retrospectively reviewed 142 cases conducted internally; 78 were treated surgically and 64 were treated using MMA embolization. We analyzed the treatment failure rate and complications, and using a binary logistic regression model, we identified treatment failure risk factors. RESULTS We found a comparable treatment failure rate of 23.1% for the surgery group and 21.9% for the MMA embolization group. However, in the MMA embolization group, 11 cases showed treatment failure due to early neurological worsening with a need for concomitant surgery. We also found a recurrence of hematoma in 15.4% of cases in the surgery group and 6.3% of cases in the MMA embolization group. CONCLUSION Both modalities have their advantages; however, correct identification is crucial for treatment success. According to our findings, hematomas with a maximal width of <18 mm, a midline shift of <5 mm, and no acute or subacute (hyperdense) hematoma could be treated with MMA embolization. Hematomas with a maximal width of >18 mm, a midline shift of >5 mm, and no membranous segmentation could have better outcomes after surgical treatment.
Collapse
Affiliation(s)
- Dalibor Sila
- Department of Neurosurgery and Interventional Neuroradiology, Donau Isar Klinikum Deggendorf, Perlasberger Str. 41, 94469 Deggendorf, Germany; (F.L.C.); (S.R.)
- Department of Neurosurgery and Neurooncology, First Faculty of Medicine, Charles University in Prague, Military University Hospital, U Vojenské Nemocnice 1200, 16902 Praha, Czech Republic;
| | - Francisco Luis Casnati
- Department of Neurosurgery and Interventional Neuroradiology, Donau Isar Klinikum Deggendorf, Perlasberger Str. 41, 94469 Deggendorf, Germany; (F.L.C.); (S.R.)
| | - Mária Vojtková
- Department of Statistics, Faculty of Economic Informatics, University of Economics in Bratislava, Dolnozemská Cesta 1/b, Bratislava 85235, Slovakia;
| | - Philipp Kirsch
- Department of Radiology and Interventional Radiology, Donau Isar Klinikum Deggendorf, Perlasberger Str. 41, 94469 Deggendorf, Germany;
| | - Stefan Rath
- Department of Neurosurgery and Interventional Neuroradiology, Donau Isar Klinikum Deggendorf, Perlasberger Str. 41, 94469 Deggendorf, Germany; (F.L.C.); (S.R.)
| | - František Charvát
- Department of Neurosurgery and Neurooncology, First Faculty of Medicine, Charles University in Prague, Military University Hospital, U Vojenské Nemocnice 1200, 16902 Praha, Czech Republic;
| |
Collapse
|
16
|
Scoville JP, Joyce E, A. Tonetti D, Bounajem MT, Thomas A, Ogilvy CS, Moore JM, Riina HA, Tanweer O, Levy EI, Spiotta AM, Gross BA, Jankowitz BT, Cawley CM, Khalessi AA, Pandey AS, Ringer AJ, Hanel R, Ortiz RA, Langer D, Levitt MR, Binning M, Taussky P, Kan P, Grandhi R. Radiographic and clinical outcomes with particle or liquid embolic agents for middle meningeal artery embolization of nonacute subdural hematomas. Interv Neuroradiol 2023; 29:683-690. [PMID: 35673710 PMCID: PMC10680958 DOI: 10.1177/15910199221104631] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 05/15/2022] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Middle meningeal artery (MMA) embolization is an apparently efficacious minimally invasive treatment for nonacute subdural hematomas (NASHs), but how different embolisates affect outcomes remains unclear. Our objective was to compare radiographic and clinical outcomes after particle or liquid MMA embolization. METHODS Patients who had MMA embolization for NASH were retrospectively identified from a multi-institution database. The primary radiographic and clinical outcomes-50% NASH thickness reduction and need for surgical retreatment within 90 days, respectively-were compared for liquid and particle embolizations in patients treated 1) without surgical intervention (upfront), 2) after recurrence, or 3) with concomitant surgery (prophylactic). RESULTS The upfront, recurrent, and prophylactic subgroups included 133, 59, and 16 patients, respectively. The primary radiographic outcome was observed in 61.8%, 61%, and 72.7% of particle-embolized patients and 61.3%, 55.6%, and 20% of liquid-embolized patients, respectively (p = 0.457, 0.819, 0.755). Hazard ratios comparing time to reach radiographic outcome in the particle and liquid groups or upfront, recurrent, andprophylactic timing were 1.31 (95% CI 0.78-2.18; p = 0.310), 1.09 (95% CI 0.52-2.27; p = 0.822), and 1.5 (95% CI 0.14-16.54; p = 0.74), respectively. The primary clinical outcome occurred in 8.0%, 2.4%, and 0% of patients who underwent particle embolization in the upfront, recurrent, and prophylactic groups, respectively, compared with 0%, 5.6%, and 0% who underwent liquid embolization (p = 0.197, 0.521, 1.00). CONCLUSIONS MMA embolization with particle and liquid embolisates appears to be equally effective in treatment of NASHs as determined by the percentage who reach, and the time to reach, 50% NASH thickness reduction and the incidence of surgical reintervention within 90 days.
Collapse
Affiliation(s)
- Jonathan P. Scoville
- Department of Neurosurgery, Clinical Neuroscience Center, University of Utah, Salt Lake City, Utah, USA
| | - Evan Joyce
- Department of Neurosurgery, Clinical Neuroscience Center, University of Utah, Salt Lake City, Utah, USA
| | | | - Michael T. Bounajem
- Department of Neurosurgery, Clinical Neuroscience Center, University of Utah, Salt Lake City, Utah, USA
| | - Ajith Thomas
- Cooper Neuroscience Institute, Camden, New Jersey, USA
| | - Christopher S. Ogilvy
- Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Justin M. Moore
- Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Howard A. Riina
- Department of Neurosurgery, NYU Langone Medical Center, New York, New York, USA
| | - Omar Tanweer
- Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
| | - Elad I. Levy
- Departments of Neurosurgery and Radiology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA
| | - Alejandro M. Spiotta
- Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Bradley A. Gross
- Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | | | | | - Alexander A. Khalessi
- Department of Neurosurgery, University of California-San Diego, La Jolla, California, USA
| | - Aditya S. Pandey
- Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA
| | - Andrew J. Ringer
- Mayfield Clinic, TriHealth Neuroscience Institute, Good Samaritan Hospital, Cincinnati, Ohio, USA
| | - Ricardo Hanel
- Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA
| | - Rafael A. Ortiz
- Department of Neurosurgery, Lenox Hill Hospital, New York, New York, USA
| | - David Langer
- Department of Neurosurgery, Lenox Hill Hospital, New York, New York, USA
| | - Michael R. Levitt
- Department of Neurological Surgery, University of Washington, Harborview Medical Center, Seattle, Washington, USA
| | - Mandy Binning
- Department of Neurosurgery, Global Neurosciences Institute Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
| | - Philipp Taussky
- Department of Neurosurgery, Clinical Neuroscience Center, University of Utah, Salt Lake City, Utah, USA
| | - Peter Kan
- Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas, USA
| | - Ramesh Grandhi
- Department of Neurosurgery, Clinical Neuroscience Center, University of Utah, Salt Lake City, Utah, USA
| |
Collapse
|
17
|
Aziz N, O'Halloran PJ, McKenna GS. Subdural haematoma in the elderly: management and outcomes of a UK Major Trauma Centre. Br J Neurosurg 2023; 37:1604-1612. [PMID: 36218868 DOI: 10.1080/02688697.2022.2122402] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Accepted: 09/04/2022] [Indexed: 11/02/2022]
Abstract
BACKGROUND An estimated 40% of all traumatic brain injury (TBI) occurs in ≥70-year-olds with a high prevalence of traumatic subdural haematoma (tSDH). It is anticipated that an expanding elderly population will lead to a proportional increase in the incidence of patients with tSDH presenting to UK trauma centres, but the long-term clinical outcomes and factors influencing functional outcomes in this patient group remain poorly understood. AIM To examine the management and clinical outcomes for elderly (≥70 years) patients diagnosed with tSDH. METHODS Patient data for this single-centre, retrospective cohort study were analysed from a Major Trauma Centre (MTC) electronic patient records between January 2013 and December 2019. RESULTS Two hundred and eighty patients were included, 43% aged 70-79, 42% aged 80-89 and 15% >90. In total, 37% underwent a surgical intervention. The 6-month survival in the severe, moderate, and mild TBI groups was 14%, 43%, and 67%, respectively. The 6-month survival in the surgical group was 58%, vs. 60% in the conservatively managed group. Surgical intervention did not significantly impact Extended Glasgow Coma Score (GOS-E) at 6 months, regardless of injury severity. Advanced age (p = 0.04), mixed intracranial injuries (p < 0.0001), craniotomies (p = 0.03), and poor premorbid performance status (p = 0.02) were associated with worse survival and functional outcomes. CONCLUSIONS Our study demonstrated that increasing age, increasing severity of TBI and poorer premorbid performance status were associated with significantly poorer 6-month survival and functional outcomes in elderly patients with tSDH. Burr hole evacuation was associated with better functional outcomes compared to craniotomy, but overall, there was no significant difference in the outcomes of the surgical and non-surgical groups. We identified strong risk factors for death and poor functional outcomes at 6-months which are important to consider when counselling patients and families about the long-term prognosis of elderly patients with tSDH and can help guide clinical decision-making.
Collapse
Affiliation(s)
- Natasha Aziz
- School of Medicine, Queen Mary University of London, London, UK
| | - Philip J O'Halloran
- Department of Neurosurgery, Royal London Hospital, London, UK
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, London, UK
| | | |
Collapse
|
18
|
Liu Z, Wang Y, Tang T, Zhang Y, Sun Y, Kuang X, Wei T, Zhou L, Peng A, Cao D, Hongsheng W, Qi W, Chenyi W, Shan Q. Time and Influencing Factors to Chronic Subdural Hematoma Resolution After Middle Meningeal Artery Embolization. World Neurosurg 2023; 179:e6-e14. [PMID: 36924886 DOI: 10.1016/j.wneu.2023.03.050] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Accepted: 03/12/2023] [Indexed: 03/17/2023]
Abstract
OBJECTIVE We sought to describe the resolution time of chronic subdural hematoma (CSDH) after middle meningeal artery embolization (MMAE) and potential variables that may affect hematoma resolution. METHODS A retrospective analysis was performed on CSDH patients between December 2018 and December 2021. Patient characteristics, radiologic manifestations, and data of hematoma resolution were recorded. Univariate and multivariate analyses were conducted to identify predictors of CSDH resolution time. RESULTS A total of 53 patients were enrolled including 53 hematomas. Only 1 participant relapsed and did not require surgical evacuation. Hematoma resolution was observed in 27 (50.9%) at 4 months and 48 (90.6%) cases at the last radiologic follow-up. The median MMAE-to-resolution time was 19 weeks (interquartile range: 8-24). The burr-hole irrigation + MMAE group showed faster hematoma resolution than MMAE alone during early follow-up periods, but no significant difference was found at 6 months. Increased thickness of residual hematoma, excessive postoperative midline shift, high-density hematoma, mixed-density hematoma, separated hematoma, and anticoagulant or antiplatelet agents used were predictive of nonresolution at 4 months as determined by univariate analysis, whereas anticoagulant or antiplatelet agents used and high-density hematoma were not significant on multivariate analysis. No significant association was noted between hematoma resolution and comorbidities or other hematoma radiologic features. CONCLUSIONS MMAE is an effective and minimally invasive treatment for CSDH with a lower recurrence rate. The median resolution time of CSDH following MMAE was 19 weeks (interquartile range: 8-24). Burr-hole irrigation contributed to early hematoma resolution but had no significant effect at 6 months. In addition, residual hematoma thickness, postoperative midline shift, and specific type of hematoma were associated with delayed hematoma resolution at 4 months.
Collapse
Affiliation(s)
- Zhensheng Liu
- Department of Interventional Radiology, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Youwei Wang
- Department of Neurosurgery, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Tieyu Tang
- Department of Neurology, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Yunfeng Zhang
- Department of Neurology, the Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
| | - Yong Sun
- Department of Interventional Radiology, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - XiongWei Kuang
- Department of Interventional Radiology, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Tingfeng Wei
- Department of Interventional Radiology, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Longjiang Zhou
- Department of Interventional Radiology, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Aijun Peng
- Department of Neurosurgery, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Demao Cao
- Department of Neurosurgery, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Wang Hongsheng
- Department of Neurosurgery, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Wentao Qi
- Department of Neurosurgery, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Wu Chenyi
- Department of Neurosurgery, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China
| | - Qing Shan
- Stroke Center, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
| |
Collapse
|
19
|
Guo C, Zhang X, Hu Z, Guo K, Li Z, Li J, Peng J. Middle Meningeal Artery Embolization Combined With Endoscopic Treatment for Chronic Subdural Hematoma. J Craniofac Surg 2023; 34:2529-2532. [PMID: 37665073 DOI: 10.1097/scs.0000000000009715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 07/03/2023] [Indexed: 09/05/2023] Open
Abstract
OBJECTIVE To explore the clinical feasibility of middle meningeal artery (MMA) embolization combined with endoscopic treatment for new or recurrent chronic subdural hematoma (CSDH). METHODS Twenty patients with CSDH treated in the Binzhou Medical University Hospital from June 2020 to October 2022 were analyzed retrospectively. The clinical information, prognosis, imaging results, and surgical results of the patients were collected and analyzed. The authors first performed MMA embolization, and then endoscopic treatment of CSDH was performed after successful embolization of MMA. Results: All 20 patients with CSDH were successfully treated with MMA embolization combined with endoscope-assisted evacuation. The symptoms of all patients were relieved, no surgical complications occurred, and no rebleeding and recurrence were found in follow-up computed tomography. CONCLUSION Middle meningeal artery embolization combined with endoscopic treatment of CSDH has a good clinical effect, and it may prevent postoperative recurrence.
Collapse
Affiliation(s)
- Chong Guo
- Department of Neurosurgery, Binzhou Medical University Hospital
| | - Xinfan Zhang
- Department of Neurosurgery, Binzhou People's Hospital, Binzhou, Shandong, China
| | - Zhongbo Hu
- Department of Neurosurgery, Binzhou Medical University Hospital
| | - Ke Guo
- Department of Neurosurgery, Binzhou Medical University Hospital
| | - Zefu Li
- Department of Neurosurgery, Binzhou Medical University Hospital
| | - Jianmin Li
- Department of Neurosurgery, Binzhou Medical University Hospital
| | - Jiangtao Peng
- Department of Neurosurgery, Binzhou Medical University Hospital
| |
Collapse
|
20
|
Omura Y, Ishiguro T. Middle meningeal artery embolization for chronic subdural hematoma: a systematic review. Front Neurol 2023; 14:1259647. [PMID: 37881312 PMCID: PMC10593964 DOI: 10.3389/fneur.2023.1259647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2023] [Accepted: 09/25/2023] [Indexed: 10/27/2023] Open
Abstract
Background Chronic subdural hematoma (cSDH) is one of the most common diseases in neurosurgery. Middle meningeal artery embolization (MMAE) is reportedly an option to prevent recurrence or avoid surgery in patients with cSDH. This study was performed to review the evidence on MMAE for cSDH and evaluate its safety, efficacy, indications, and feasibility. Methods We systematically reviewed the literature according to the PRISMA guidelines using an electronic database. The search yielded 43 articles involving 2,783 patients who underwent MMAE. Results The hematoma resolution, recurrence, and retreatment rates in the MMAE-alone treatment group (n = 815) were 86.7%, 6.3%, and 9.6%, respectively, whereas those in the prophylactic MMAE with combined surgery group (n = 370) were 95.6%, 4.4%, and 3.4%, respectively. The overall MMAE-related complication rate was 2.3%. Conclusion This study shows that MMAE alone is, although not immediate, as effective as evacuation surgery alone in reducing hematoma. The study also shows that combined treatment has a lower recurrence rate than evacuation surgery alone. Because MMAE is a safe procedure, it should be considered for patients with cSDH, especially those with a high risk of recurrence.
Collapse
Affiliation(s)
| | - Taichi Ishiguro
- Department of Neurosurgery, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Chiba, Japan
| |
Collapse
|
21
|
Sioutas GS, Mouchtouris N, Saiegh FA, Naamani KE, Amllay A, Becerril-Gaitan A, Velagapudi L, Gooch MR, Herial NA, Jabbour P, Rosenwasser RH, Tjoumakaris SI. Middle Meningeal Artery Embolization for Subdural Hematoma: An Institutional Cohort and Propensity Score-Matched Comparison with Conventional Management. Clin Neurol Neurosurg 2023; 233:107895. [PMID: 37556969 DOI: 10.1016/j.clineuro.2023.107895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Revised: 07/10/2023] [Accepted: 07/11/2023] [Indexed: 08/11/2023]
Abstract
BACKGROUND The treatment of non-acute subdural hematoma (NASDH) is challenging due to its high recurrence rates and comorbidities of mostly elderly patients. Middle meningeal artery embolization (MMAE) recently emerged as an alternative to surgery in the treatment of NASDH. OBJECTIVE To describe a single center's experience of MMAE with Onyx for NASDH and compare it to a surgically treated historical cohort. METHODS We performed a retrospective analysis of patients undergoing MMAE for NASDH from 2019 to 2021. MMAE was performed with ethylene vinyl alcohol copolymer (Onyx). Comparisons were made with a historical cohort from 2010 to 2018 who underwent surgical evacuation only, before and after propensity score matching. Outcomes were assessed clinically and radiographically. RESULTS We included 44 consecutive patients (55 MMAEs) who underwent MMAE, with a median follow-up of 63.5 days. Twenty-four NASDHs underwent upfront embolization, 17 adjunctive, and 14 for recurrence after prior surgical evacuation, with no significant differences in hematoma and mRS reduction between them. Two patients died during hospitalization and 2 during follow-up, unrelated to the procedure. Mean SDH thickness decreased by 48.3% ± 38.1% (P < 0.001) on last follow-up, which did not correlate with the amount of Onyx injected. Six (13.6%) patients required surgical rescue after embolization. There were no procedure-related complications. The mean modified Rankin Scale (mRS) on admission was 2.8 ± 1.5, which decreased significantly to 1 [1,4] at the last follow-up (P = 0.033). The MMAE (41 hematomas; upfront and adjunctive embolization) and Surgical Evacuation-only (461 hematomas) cohorts were balanced with propensity score mathing. Matching was successful for 41 MMAE and 41 surgical-only hematoma pairs, and only hypertension remained significantly different between the two groups, but there was no significant difference in any outcome. CONCLUSION MMAE for NASDH seems safe and effective in appropriately selected patients, non-inferior to surgery, and may become a minimally-invasive alternative. Given our encouraging results, large-scale clinical randomized trials are warranted.
Collapse
Affiliation(s)
- Georgios S Sioutas
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Nikolaos Mouchtouris
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Fadi Al Saiegh
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Kareem El Naamani
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Abdelaziz Amllay
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Andrea Becerril-Gaitan
- Department of Neurosurgery, The University of Texas Health Science Center, Houston, TX, USA
| | - Lohit Velagapudi
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - M Reid Gooch
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Nabeel A Herial
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Pascal Jabbour
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Robert H Rosenwasser
- Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | | |
Collapse
|
22
|
Zuo Q, Ni W, Yang P, Gu Y, Yu Y, Yang H, Majoie CBLM, Goyal M, Liu J, Mao Y. Managing non-acute subdural hematoma using liquid materials: a Chinese randomized trial of middle meningeal artery treatment (MAGIC-MT)-protocol. Trials 2023; 24:586. [PMID: 37710274 PMCID: PMC10503047 DOI: 10.1186/s13063-023-07608-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Accepted: 08/28/2023] [Indexed: 09/16/2023] Open
Abstract
BACKGROUND The conventional treatments for non-acute subdural hematoma (SDH) are facing the challenge of high hematoma recurrence and progression. A novel treatment of middle meningeal artery (MMA) embolization showed the potential role in decreasing the recurrence and progression rate of SDH compared to conventional treatments in multiple cohort studies. A randomized controlled trial is warranted to determine the effectiveness and safety of MMA embolization for non-acute hematoma and whether MMA embolization is superior to conventional treatments to lower the symptomatic recurrence and progression rate of non-acute SDH. METHODS This is an investigator-initiated, multi-center, prospective, open-label parallel group trial with blinded outcome assessment (PROBE design) assessing superiority of MMA embolization compared to conventional treatments. A total of 722 patients are planned to be randomized 1:1 to receive MMA embolization (intervention) or conventional treatments (control). The primary outcome is the symptomatic SDH recurrence/progression rate within 90 ± 14 days post-randomization. DISCUSSION This trial will clarify whether MMA embolization could reduce the recurrence or progression rate of symptomatic non-acute SDH compared to conventional treatment. TRIAL REGISTRATION ClinicalTrials.gov. Identifier: NCT04700345, Registered on 7 January 2021.
Collapse
Affiliation(s)
- Qiao Zuo
- Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China
| | - Wei Ni
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
| | - Pengfei Yang
- Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China
| | - Yuxiang Gu
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
| | - Ying Yu
- Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China
| | - Heng Yang
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
| | - Charles B L M Majoie
- Department of Radiology & Nuclear Medicine, Amsterdam University Medical Center, Location University of Amsterdam, Amsterdam, The Netherlands
| | - Mayank Goyal
- Departments of Clinical Neuroscience and Radiology, Hotchkiss Brain Institute, Cummings School of Medicine, University of Calgary, Calgary, AB, Canada
| | - Jianmin Liu
- Neurovascular Center, Changhai Hospital, Naval Medical University, Shanghai, China.
| | - Ying Mao
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
| |
Collapse
|
23
|
Rojas-Villabona A, Mohamed S, Kennion O, Padmanabhan R, Siddiqui A, Prasad M, Mukerji N. A systematic review of middle meningeal artery embolization for minimally symptomatic chronic subdural haematomas that do not require immediate evacuation. BRAIN & SPINE 2023; 3:102672. [PMID: 38021007 PMCID: PMC10668091 DOI: 10.1016/j.bas.2023.102672] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/03/2023] [Revised: 08/30/2023] [Accepted: 09/05/2023] [Indexed: 12/01/2023]
Abstract
Introduction Embolization of the Middle Meningeal Artery (EMMA) is an emerging treatment option for patients with Chronic Subdural Haematoma (CSDH). Questions (1) Can EMMA change the natural history of untreated minimally symptomatic CSDH which do not require immediate evacuation? (2) What is the role of EMMA in the prevention of recurrence following surgical treatment? (3) Can the procedure be performed under local anaesthetic? Material and methods Systematic literature review. No randomised clinical trials available on EMMA for meta-analysis. Results Six unique large cohorts with more than 50 embolisations were identified (evidence: 3b-4). EMMA can control the progression of surgically naïve CSDH in 91.1-100% of the patients, in which haematoma expansion is halted, or the lesion decreases and resolves. Treatment failure requiring surgery occurs in 0-4.1% of the patients having EMMA as the primary and only treatment. Treatment failure requiring surgery goes up slightly to 6.8% if post-surgical patients are included. When EMMA is used as postsurgical adjunctive the risk of recurrence is 1.4-8.9% compared to 10-20% in surgical series. EMMA has minimal morbidity and it is feasible under local anaesthesia or slight sedation in the majority of cases. Conclusion There is cumulative low-quality evidence in the literature that EMMA may be able to modify the natural course of the disease. It appears effective in controlling progression of CSDHs in patients having it as a primary standing alone treatment and it reduces the risk of recurrence and the need for surgical intervention in refractory postsurgical cases or as a postsurgical adjunctive treatment with minimal morbidity (recommendation: C).
Collapse
Affiliation(s)
| | - Saffwan Mohamed
- Department of Neurosurgery, James Cook University Hospital, Middlesbrough, UK
| | - Oliver Kennion
- Department of Neurosurgery, James Cook University Hospital, Middlesbrough, UK
| | - Rajeev Padmanabhan
- Department of Neuroradiology, James Cook University Hospital, Middlesbrough, UK
| | - Aslam Siddiqui
- Department of Neuroradiology, James Cook University Hospital, Middlesbrough, UK
| | - Manjunath Prasad
- Department of Neurosurgery, James Cook University Hospital, Middlesbrough, UK
| | - Nitin Mukerji
- Department of Neurosurgery, James Cook University Hospital, Middlesbrough, UK
| |
Collapse
|
24
|
Mowla A, Abdollahifard S, Farrokhi A, Yousefi O, Valibeygi A, Azami P. Middle Meningeal Artery Embolization with Liquid Embolic Agents for Chronic Subdural Hematoma: A Systematic Review and Meta-analysis. J Vasc Interv Radiol 2023; 34:1493-1500.e7. [PMID: 37182671 DOI: 10.1016/j.jvir.2023.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 04/03/2023] [Accepted: 05/04/2023] [Indexed: 05/16/2023] Open
Abstract
PURPOSE To assess the efficacy and safety of middle meningeal artery (MMA) embolization with liquid embolic agents and the outcomes of patients following this procedure. MATERIALS AND METHODS A review of the literature was conducted to identify studies investigating the efficacy and safety of MMA embolization with liquid embolic agents in patients with chronic subdural hematoma (cSDH) in PubMed, Scopus, Embase, and Web of Science. The keywords "liquid embolic agent," "middle meningeal artery," "cSDH," and "embolization" as well as their synonyms were used to build up the search strategy. The R statistical software and random-effects model were used for analysis. Heterogeneity was reported as I2, and publication bias was calculated using the Egger test. RESULTS Of 628 articles retrieved, 14 studies were eligible to be included in this study. Data of 276 patients were analyzed. n-Butyl cyanoacrylate and ethylene vinyl alcohol copolymer were the most commonly used embolic agents. This study revealed a pooled mortality rate of 0% (95% confidence interval [CI], 0.00%-100%), recurrence and failure rate of 3% (95% CI, 1%-10%), reoperation/reintervention rate of 4% (95% CI, 2%-12%), rate of size decrease of 94% (95% CI, 79%-98%), technical success rate of 100% (95% CI, 76%-100%), and adverse event rate of 1% (95% CI, 0.00%-4%). CONCLUSIONS With low mortality, recurrence, reoperation, and adverse event rates and a remarkable decrease in the size of hematomas, MMA embolization with liquid embolic agents may be considered a safe and effective treatment option in patients in whom surgical intervention has previously failed and as an alternative to conventional treatments.
Collapse
Affiliation(s)
- Ashkan Mowla
- Division of Stroke and Endovascular Neurosurgery, Department of Neurological Surgery, Keck School of Medicine, University of Southern California (USC), Los Angeles, California.
| | - Saeed Abdollahifard
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz; Research Center for Neuromodulation and Pain, Shiraz
| | - Amirmohammad Farrokhi
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz; Research Center for Neuromodulation and Pain, Shiraz
| | - Omid Yousefi
- Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz
| | - Adib Valibeygi
- Fasa Neuroscience Circle, Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
| | - Pouria Azami
- Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz
| |
Collapse
|
25
|
Wang C, Liu C. Surgical treatment of chronic subdural hematoma by twist drill craniotomy: A 9-year, single-center experience of 219 cases. Clin Neurol Neurosurg 2023; 232:107891. [PMID: 37451089 DOI: 10.1016/j.clineuro.2023.107891] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 07/09/2023] [Accepted: 07/10/2023] [Indexed: 07/18/2023]
Abstract
OBJECTIVE This study aims to assess the safety and efficiency of twist drill craniotomy (TDC) for surgical treatment of chronic subdural hematoma (CSDH) based on a single-center experience of 219 cases performed over nine years. METHODS We performed a retrospective analysis of CSDH patients who underwent TDC treatment in our hospital between January 2013 and December 2021. Clinical and radiological characteristics, as well as surgical outcomes of the included patients, were reviewed and analyzed. Factors that may affect hematoma recurrence and outcomes were also investigated. RESULTS A total of 219 patients (186 males and 33 females) were included. Eighteen (8.2%) patients experienced postoperative complications. The in-hospital mortality and recurrence rates in our series were 0.5% (1/219) and 4.1% (9/217), respectively. 91.7% (199/217) of patients achieved favorable outcomes six months after the operation. Duration of drainage catheter (odds ratio [OR] 0.135, 95% confidence interval [CI] 0.017-1.099; P = 0.030) was the only factor significantly related to the recurrence of CSDH. Moreover, brain infarction (OR 5.175, 95% CI 1.417-18.896; P = 0.013), Alzheimer's disease (OR 20.515, 95% CI 1.950-215.840; P = 0.012), and preoperative dysfunction of coagulation (OR 6.509, 95% CI 1.501-28.217; P = 0.012) were markedly associated with unfavorable functional outcomes. CONCLUSION TDC with irrigation and closed-system drainage is a minimally invasive, simple, safe, and effective surgical technique that can serve as the first-choice for the treatment of CSDH with a low recurrence rate.
Collapse
Affiliation(s)
- Chengjun Wang
- Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong'an Road, Xicheng District, Beijing 100050, People's Republic of China
| | - Cang Liu
- Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong'an Road, Xicheng District, Beijing 100050, People's Republic of China.
| |
Collapse
|
26
|
Diana F, Romoli M, Ricchetti F, Milonia L, Salcuni A, Cirelli C, Ruzza AD, Gaudino C, Iacobucci M, Biraschi F. Lidocaine for headache prevention during chronic subdural hematoma embolization. Interv Neuroradiol 2023:15910199231198909. [PMID: 37649347 DOI: 10.1177/15910199231198909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023] Open
Abstract
BACKGROUND Middle meningeal artery embolization (MMAE) for the management of chronic subdural hematomas (CSDH) with ethylene vinyl alcohol (EVOH) causes an evident patient discomfort due to meningeal nociceptors stimulation. The aim of this study was to assess safety and efficacy of intra-arterial lidocaine (IAL) before MMAE of CSDH with EVOH. METHODS We analyzed all consecutive patients with bilateral CSDH undergoing MMAE with EVOH. We used a monolateral IAL injection, with casual allocation. We assessed the headache felt by patients during embolization with the visual analog scale (VAS) and compared scores obtained after embolization of both sides. We followed the STROBE guidelines for case-control studies. Paired t-test and χ2 test were used to compare the distribution of variables in IAL vs control group. RESULTS Between September 2021 and March 2023, 32 patients underwent bilateral MMAE with EVOH for a CSDH. Lidocaine treatment resulted in a substantially lower VAS score compared to the control group (median 3 vs 7, p < 0.001), with no substantial side effect. Compliance also benefited from lidocaine administration. CONCLUSIONS In patients with CSDH undergoing MMAE, IAL seems to reduce pain sensation associated with EVOH injection and to increase patients' compliance during treatment.
Collapse
Affiliation(s)
- Francesco Diana
- Interventional Neuroradiology, Vall d'Hebron University Hospital, Barcelona, Spain
- Stroke Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
| | - Michele Romoli
- Neurology and Stroke Unit, Maurizio Bufalini Hospital, Cesena, Italy
| | - Francesca Ricchetti
- Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Italy
| | - Luca Milonia
- Department of Human Neurosciences, Interventional Neuroradiology, Policlinico Umberto I, Sapienza University of Rome, Italy
| | - Andrea Salcuni
- Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Italy
| | - Carlo Cirelli
- Department of Human Neurosciences, Interventional Neuroradiology, Policlinico Umberto I, Sapienza University of Rome, Italy
| | - Alberto Di Ruzza
- Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Italy
| | - Chiara Gaudino
- Department of Human Neurosciences, Interventional Neuroradiology, Policlinico Umberto I, Sapienza University of Rome, Italy
| | - Marta Iacobucci
- Department of Human Neurosciences, Interventional Neuroradiology, Policlinico Umberto I, Sapienza University of Rome, Italy
| | - Francesco Biraschi
- Department of Human Neurosciences, Interventional Neuroradiology, Policlinico Umberto I, Sapienza University of Rome, Italy
| |
Collapse
|
27
|
Orscelik A, Senol YC, Bilgin C, Kobeissi H, Arul S, Cloft H, Lanzino G, Kallmes DF, Brinjikji W. Middle meningeal artery embolization combined with surgical evacuation for chronic subdural hematoma: A single-center experience of 75 cases. Interv Neuroradiol 2023:15910199231196453. [PMID: 37635326 DOI: 10.1177/15910199231196453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/29/2023] Open
Abstract
BACKGROUND Chronic subdural hematoma (cSDH) is a challenging and common neurosurgical condition. Our goal is to demonstrate that middle meningeal artery (MMA) embolization combined with surgical evacuation can be a promising adjuvant option for treatment of cSDHs and prevent recurrence in symptomatic patients who require surgical treatment. METHOD We retrospectively collected data from patients who underwent MMA embolization using polyvinyl alcohol particles and surgical evacuation with burr hole or craniotomy in a single center for the treatment of new and recurrent cSDHs. The primary outcome was recurrence of cSDH requiring surgical rescue during follow up, and secondary outcomes were defined as >50% decrease in the maximum width of cSDHs on the longest follow-up computed tomography (CT) scan, complications following procedure, and improvement in modified Rankin scale (mRS) score. RESULTS A total of 51 patients successfully underwent 72 MMA embolization procedures (96% of the total 75 cases in the cohort) combined with surgical evacuation. Seventy cases (93.3%) achieved at least 50% reduction in the size of the cSDHs on the last CT imaging. A surgical evacuation was required in five cases (6.7%) due to cSDH recurrence during the follow-up period. There were three complications (6.0%) related to embolization procedure. Forty patients (78.4%) showed improvement in mRS score. There was one mortality (2%) regardless of the embolization and evacuation. CONCLUSIONS Our study demonstrates the safety and efficacy of adjunct MMA embolization in significantly reducing size and recurrence of cSDHs.
Collapse
Affiliation(s)
| | - Yigit Can Senol
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
- Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA
| | - Cem Bilgin
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | | | - Santhosh Arul
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Harry Cloft
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Giuseppe Lanzino
- Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA
| | | | - Waleed Brinjikji
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
- Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
28
|
Dowlati E, Chesney K, Carpenter AB, Rock M, Patel N, Mai JC, Liu AH, Armonda RA, Felbaum DR. Awake transradial middle meningeal artery embolization and twist drill craniostomy for chronic subdural hematomas in the elderly: case series and technical note. J Neurosurg Sci 2023; 67:471-479. [PMID: 34114433 DOI: 10.23736/s0390-5616.21.05335-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Due to prohibitive perioperative risk factors, optimal treatment for chronic subdural hematomas (cSDH) in the elderly remains unclear. Minimally invasive techniques are a viable option and include bedside subdural evacuation port system (SEPS), as well as prevention of recurrence with middle meningeal artery (MMA) embolization. We present a case series of elderly patients undergoing combined transradial MMA embolization and bed-side craniostomy as primary treatment for cSDH. METHODS Patients 70 years and older from 2019 to 2020 that underwent single setting, awake transradial MMA embolization with concurrent SEPS placement under local anesthesia were included. Those with prior treatments, interventions performed under general anesthesia, or with less than 60-day follow-up were excluded. Descriptive analyses of baseline characteristics, radiologic parameters, comorbidities, and outcome measures were completed. RESULTS Twenty elderly patients (mean age of 81.0 years) with multiple comorbidities underwent 28 MMA embolization+SEPS procedures as primary treatment for cSDH. Mean cSDH thickness was 1.8cm±0.6 cm with 7.3±3.9 mm midline shift. All patients tolerated the procedure well. 1/20 (5.0%) patients died within 30 days of the procedure. A majority of patients were discharged to home (12/20; 60.0%). There was an average of 3.6-month follow-up and one patient (5.0%) developed recurrence in the follow-up period requiring further intervention. CONCLUSIONS In select elderly patients with high perioperative risk factors, primary treatment of cSDH using awake transradial MMA embolization+SEPS placement is a minimally invasive, feasible, and safe option. Further comparative studies are warranted to evaluate efficacy of the treatment.
Collapse
Affiliation(s)
- Ehsan Dowlati
- Department of Neurosurgery, MedStar Georgetown University Hospital, Washington, DC, USA -
| | - Kelsi Chesney
- Department of Neurosurgery, MedStar Georgetown University Hospital, Washington, DC, USA
| | | | - Mitchell Rock
- Georgetown University School of Medicine, Washington, DC, USA
| | - Nirali Patel
- Department of Neurosurgery, MedStar Georgetown University Hospital, Washington, DC, USA
| | - Jeffrey C Mai
- Department of Neurosurgery, MedStar Georgetown University Hospital, Washington, DC, USA
- Department of Neurosurgery, MedStar Washington Hospital Center, Washington, DC, USA
| | - Ai-Hsi Liu
- Department of Radiology, MedStar Washington Hospital Center, Washington, DC, USA
| | - Rocco A Armonda
- Department of Neurosurgery, MedStar Georgetown University Hospital, Washington, DC, USA
- Department of Neurosurgery, MedStar Washington Hospital Center, Washington, DC, USA
| | - Daniel R Felbaum
- Department of Neurosurgery, MedStar Georgetown University Hospital, Washington, DC, USA
- Department of Neurosurgery, MedStar Washington Hospital Center, Washington, DC, USA
| |
Collapse
|
29
|
Rodriguez B, Morgan I, Young T, Vlastos J, Williams T, Hrabarchuk EI, Tepper J, Baker T, Kellner CP, Bederson J, Rapoport BI. Surgical techniques for evacuation of chronic subdural hematoma: a mini-review. Front Neurol 2023; 14:1086645. [PMID: 37456631 PMCID: PMC10338715 DOI: 10.3389/fneur.2023.1086645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 05/30/2023] [Indexed: 07/18/2023] Open
Abstract
Chronic subdural hematoma is one of the most common neurosurgical pathologies with over 160,000 cases in the United States and Europe each year. The current standard of care involves surgically evacuating the hematoma through a cranial opening, however, varied patient risk profiles, a significant recurrence rate, and increasing financial burden have sparked innovation in the field. This mini-review provides a brief overview of currently used evacuation techniques, including emerging adjuncts such as endoscopic assistance and middle meningeal artery embolization. This review synthesizes the body of available evidence on efficacy and risk profiles for each critical aspect of surgical technique in cSDH evacuation and provides insight into trends in the field and promising new technologies.
Collapse
Affiliation(s)
- Benjamin Rodriguez
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Isabella Morgan
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
| | - Tirone Young
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Joseph Vlastos
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Tyree Williams
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Rensselaer Polytechnic Institute, Troy, NY, United States
| | - Eugene I. Hrabarchuk
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Jaden Tepper
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
| | - Turner Baker
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
| | - Christopher P. Kellner
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Joshua Bederson
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| | - Benjamin I. Rapoport
- Mount Sinai BioDesign, Mount Sinai Medical System, New York, NY, United States
- Department of Neurosurgery, Mount Sinai Medical System, New York, NY, United States
- Icahn School of Medicine, New York, NY, United States
| |
Collapse
|
30
|
Khorasanizadeh M, Shutran M, Garcia A, Enriquez-Marulanda A, Moore J, Ogilvy CS, Thomas AJ. Middle meningeal artery embolization for treatment of chronic subdural hematomas: does selection of embolized branches affect outcomes? J Neurosurg 2023; 138:1494-1502. [PMID: 36681986 DOI: 10.3171/2022.9.jns221663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Accepted: 09/26/2022] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Middle meningeal artery (MMA) embolization (MMAE) is a new therapeutic modality for chronic subdural hematoma (cSDH). There is limited evidence comparing various MMAE procedural techniques, resulting in significant variations in technique and procedural planning. The objective of this study was to compare outcomes of MMAE by the number and location of MMA branches that were embolized. METHODS A single-center retrospective study of patients with cSDH treated by MMAE was conducted. Clinical outcomes, need for re-intervention, and changes in hematoma size were compared between different MMAE techniques. RESULTS Ninety-four cSDHs in 78 patients were included. Embolization of the proximal trunk only, distal branches only, or proximal trunk plus distal branches resulted in similar rates of need for rescue surgery (7.4%, 13.0%, and 6.8%, respectively; p = 0.66) and rates of reducing the volume of the hematoma by at least 50% (74.1%, 80.0%, and 77.5%, respectively; p = 0.88). Embolization of only one branch had similar outcomes to embolization of more than one branch, as rescue surgery rates were 9.3% and 7.8% (p = 0.80), and rates ≥ 50% volume reduction were 75.6% and 78.3% (p = 0.76), respectively. Selective embolization of the dominant MMA branch was not associated with significantly different outcomes. CONCLUSIONS Outcomes of distal, proximal, or combined proximal and distal MMAE in cSDH are not significantly different. Embolization of more than one branch is not associated with improved treatment efficacy. Arguably, targeting any location in the MMA provides sufficient flow restriction to enable spontaneous hematoma resolution. Accordingly, a technical planning algorithm for cSDH MMAE is suggested.
Collapse
Affiliation(s)
- MirHojjat Khorasanizadeh
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Max Shutran
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Alfonso Garcia
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Alejandro Enriquez-Marulanda
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Justin Moore
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Christopher S Ogilvy
- 1Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and
| | - Ajith J Thomas
- 2Department of Neurological Surgery, Cooper University Health Care, Cooper Medical School of Rowan University, Camden, New Jersey
| |
Collapse
|
31
|
Sattari SA, Yang W, Shahbandi A, Feghali J, Lee RP, Xu R, Jackson C, Gonzalez LF, Tamargo RJ, Huang J, Caplan JM. Middle Meningeal Artery Embolization Versus Conventional Management for Patients With Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis. Neurosurgery 2023; 92:1142-1154. [PMID: 36929762 DOI: 10.1227/neu.0000000000002365] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 11/15/2022] [Indexed: 03/18/2023] Open
Abstract
BACKGROUND The results from studies that compare middle meningeal artery (MMA) embolization vs conventional management for patients with chronic subdural hematoma are varied. OBJECTIVE To conduct a systematic review and meta-analysis on studies that compared MMA embolization vs conventional management. METHODS Medline, PubMed, and Embase databases were searched. Primary outcomes were treatment failure and surgical rescue; secondary outcomes were complications, follow-up modified Rankin scale > 2, mortality, complete hematoma resolution, and length of hospital stay (day). The certainty of the evidence was determined using the GRADE approach. RESULTS Nine studies yielding 1523 patients were enrolled, of which 337 (22.2%) and 1186 (77.8%) patients received MMA embolization and conventional management, respectively. MMA embolization was superior to conventional management for treatment failure (relative risk [RR] = 0.34 [0.14-0.82], P = .02), surgical rescue (RR = 0.33 [0.14-0.77], P = .01), and complete hematoma resolution (RR = 2.01 [1.10-3.68], P = .02). There was no difference between the 2 groups for complications (RR = 0.93 [0.63-1.37], P = .72), follow-up modified Rankin scale >2 (RR = 0.78 [0.449-1.25], P = .31), mortality (RR = 1.05 [0.51-2.14], P = .89), and length of hospital stay (mean difference = -0.57 [-2.55, 1.41], P = .57). For MMA embolization, the number needed to treat for treatment failure, surgical rescue, and complete hematoma resolution was 7, 9, and 3, respectively. The certainty of the evidence was moderate to high for primary outcomes and low to moderate for secondary outcomes. CONCLUSION MMA embolization decreases treatment failure and the need for surgical rescue without furthering the risk of morbidity and mortality. The authors recommend considering MMA embolization in the chronic subdural hematoma management.
Collapse
Affiliation(s)
- Shahab Aldin Sattari
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Wuyang Yang
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Ataollah Shahbandi
- Tehran School of Medicine, Tehran University of Medical Science, Tehran, Iran
| | - James Feghali
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Ryan P Lee
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Risheng Xu
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Christopher Jackson
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - L Fernando Gonzalez
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Rafael J Tamargo
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Judy Huang
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Justin M Caplan
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| |
Collapse
|
32
|
Lam A, Selvarajah D, Htike SS, Chan S, Lalloo S, Lock G, Redmond K, Leggett D, Mews P. The efficacy of postoperative middle meningeal artery embolization on chronic subdural hematoma - A multicentered randomized controlled trial. Surg Neurol Int 2023; 14:168. [PMID: 37292400 PMCID: PMC10246309 DOI: 10.25259/sni_208_2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2023] [Accepted: 04/25/2023] [Indexed: 06/10/2023] Open
Abstract
Background Middle meningeal artery (MMA) embolization has recently emerged as a potential treatment for chronic subdural hematoma (cSDH). Numerous retrospective studies have suggested that it can potentially reduce the risk of hematoma recurrence following surgical evacuation. We have conducted a randomized controlled trial to investigate the effectiveness of postoperative MMA embolization in reducing recurrence rate, residual hematoma thickness as well as improving functional outcome. Methods Patients aged 18 or above were recruited. Following evacuation through burr hole or craniotomy, patients were randomly allocated to undergo either MMA embolization or standard care (monitoring). The primary outcome was symptomatic recurrence requiring redo evacuation. Secondary outcomes include residual hematoma thickness and modified Rankin Scale (mRS) at 6 weeks and 3 months. Results Thirty-six patients (41 cSDHs) were recruited between April 2021 and September 2022. Seventeen patients (19 cSDHs) were allocated to the embolization group and 19 patients (22 cSDHs) were in the control group. No symptomatic recurrence was observed in the treatment group while 3 control patients (15.8%) underwent repeat surgery for symptomatic recurrence, however, it was not statistically significant (P = 0.234). Furthermore, there was no significant difference in residual hematoma thickness at 6 weeks or 3 months between the two groups. All patients in the embolization group had a good functional outcome (mRS 0-1) at 3 months, which was significantly higher than the 53% observed in the control group. No complications related to MMA embolization were reported. Conclusion Further study with larger sample size is required to evaluate the efficacy of MMA embolization.
Collapse
Affiliation(s)
- Alexander Lam
- Department of Neurosurgery, Princess Alexandra Hospital, Woolloongabba, Australia
| | | | - Soe San Htike
- Department of Neurosurgery, Princess Alexandra Hospital, Woolloongabba, Australia
| | - Sophia Chan
- Department of Neurosurgery, Princess Alexandra Hospital, Woolloongabba, Australia
| | | | - Gregory Lock
- Department of Radiology, Princess Alexandra Hospital, Woolloongabba, Australia
| | - Kendal Redmond
- Department of Radiology, Princess Alexandra Hospital, Woolloongabba, Australia
| | - David Leggett
- Department of Radiology, Princess Alexandra Hospital, Woolloongabba, Australia
| | - Peter Mews
- Department of Neurosurgery, Canberra Hospital, Garran, Australia
| |
Collapse
|
33
|
Uttam BK, Yuanyuan L, Bizhan A, Thorsten FR, Mazhar K, Marco C, Dheeraj G. Short-term follow-up pilot study of sole middle meningeal artery embolization for chronic subdural hematoma: influence of internal architecture on the radiological outcomes. Neuroradiology 2023:10.1007/s00234-023-03158-1. [PMID: 37165110 DOI: 10.1007/s00234-023-03158-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Accepted: 04/25/2023] [Indexed: 05/12/2023]
Abstract
PURPOSE To identify prognostic factors with emphasis on chronic subdural hematoma (CSDH) architecture that determines short-term outcome of middle meningeal artery embolization (MMAE). METHODS Consecutive CSDH patients treated by MMAE (November 2019 and March 2022) were retrospectively analyzed. Four architectures were analyzed: homogeneous, laminar, separated, and trabecular types. Predictor variables from baseline CT were correlated with radiological endpoint (≥ 50% of hematoma volume reduction), time to reach the endpoint, and rate of volume reduction. RESULTS Study included 50 patients with 56 CSDHs (median age [first quartile, Q1; third quartile, Q3] 70.5 [60, 78.3] years; 36 were men). Separated type reached the endpoint at a lower rate on both bivariate (p = 0.02) and multivariate Cox model (0.034). Kaplan-Meier curves demonstrated that the median [Q1, Q3] time for 50% of the hematomas to reach the endpoint was 5 [4, 8], 4 [3, 5], 15 [15, 15], and 11 [4, 19] weeks for homogeneous, laminar, separated, and trabecular types, respectively. Linear mixed-effect model demonstrated a significant variation in the slope of hematoma volume reduction that was - 4.16 (95% confidence interval [CI] - 5.4, - 2.9), - 6.7 (95% CI - 8.35, - 5.1), - 2.03 (95% CI - 4.14, 0.08), and - 5.06 (95% CI - 6.8, - 3.32) ml per week for homogeneous, laminar, separated, and trabecular subtypes, respectively. CONCLUSION Separated CSDH is a poor prognostic type in achieving radiological endpoint and a slower rate of volume reduction. While, homogeneous and laminar types reached the endpoint faster than separated and trabecular types on short-term follow-up.
Collapse
Affiliation(s)
- Bodanapally K Uttam
- Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, 22S Greene Street, Baltimore, MD, 21201, USA.
| | - Liang Yuanyuan
- Division of Biostatistics and Bioinformatics109B, University of Maryland School of Medicine, 660 W. Redwood Street, MD, 21201, Howard Hall Baltimore, USA
| | - Aarabi Bizhan
- Department of Neurosurgery, University of Maryland School of Medicine, 22 S Greene Street, Suite S-12-D, Baltimore, MD, 21201, USA
| | - Fleiter R Thorsten
- Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, 22S Greene Street, Baltimore, MD, 21201, USA
| | - Khalid Mazhar
- Department of Neurology, University of Maryland School of Medicine, 22S Greene Street, Baltimore, MD, 21201, USA
| | - Colasurdo Marco
- Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, 22S Greene Street, Baltimore, MD, 21201, USA
| | - Gandhi Dheeraj
- Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, 22S Greene Street, Baltimore, MD, 21201, USA
| |
Collapse
|
34
|
Salem MM, Kuybu O, Nguyen Hoang A, Baig AA, Khorasanizadeh M, Baker C, Hunsaker JC, Mendez AA, Cortez G, Davies JM, Narayanan S, Cawley CM, Riina HA, Moore JM, Spiotta AM, Khalessi AA, Howard BM, Hanel R, Tanweer O, Levy EI, Grandhi R, Lang MJ, Siddiqui AH, Kan P, Ogilvy CS, Gross BA, Thomas AJ, Jankowitz BT, Burkhardt JK. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Predictors of Clinical and Radiographic Failure from 636 Embolizations. Radiology 2023; 307:e222045. [PMID: 37070990 PMCID: PMC10323293 DOI: 10.1148/radiol.222045] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Revised: 01/25/2023] [Accepted: 03/01/2023] [Indexed: 04/19/2023]
Abstract
Background Knowledge regarding predictors of clinical and radiographic failures of middle meningeal artery (MMA) embolization (MMAE) treatment for chronic subdural hematoma (CSDH) is limited. Purpose To identify predictors of MMAE treatment failure for CSDH. Materials and Methods In this retrospective study, consecutive patients who underwent MMAE for CSDH from February 2018 to April 2022 at 13 U.S. centers were included. Clinical failure was defined as hematoma reaccumulation and/or neurologic deterioration requiring rescue surgery. Radiographic failure was defined as a maximal hematoma thickness reduction less than 50% at last imaging (minimum 2 weeks of head CT follow-up). Multivariable logistic regression models were constructed to identify independent failure predictors, controlling for age, sex, concurrent surgical evacuation, midline shift, hematoma thickness, and pretreatment baseline antiplatelet and anticoagulation therapy. Results Overall, 530 patients (mean age, 71.9 years ± 12.8 [SD]; 386 men; 106 with bilateral lesions) underwent 636 MMAE procedures. At presentation, the median CSDH thickness was 15 mm and 31.3% (166 of 530) and 21.7% (115 of 530) of patients were receiving antiplatelet and anticoagulation medications, respectively. Clinical failure occurred in 36 of 530 patients (6.8%, over a median follow-up of 4.1 months) and radiographic failure occurred in 26.3% (137 of 522) of procedures. At multivariable analysis, independent predictors of clinical failure were pretreatment anticoagulation therapy (odds ratio [OR], 3.23; P = .007) and an MMA diameter less than 1.5 mm (OR, 2.52; P = .027), while liquid embolic agents were associated with nonfailure (OR, 0.32; P = .011). For radiographic failure, female sex (OR, 0.36; P = .001), concurrent surgical evacuation (OR, 0.43; P = .009), and a longer imaging follow-up time were associated with nonfailure. Conversely, MMA diameter less than 1.5 mm (OR, 1.7; P = .044), midline shift (OR, 1.1; P = .02), and superselective MMA catheterization (without targeting the main MMA trunk) (OR, 2; P = .029) were associated with radiographic failure. Sensitivity analyses retained these associations. Conclusion Multiple independent predictors of failure of MMAE treatment for chronic subdural hematomas were identified, with small diameter (<1.5 mm) being the only factor independently associated with both clinical and radiographic failures. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Chaudhary and Gemmete in this issue.
Collapse
Affiliation(s)
- Mohamed M. Salem
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Okkes Kuybu
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Alex Nguyen Hoang
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Ammad A. Baig
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Mirhojjat Khorasanizadeh
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Cordell Baker
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Joshua C. Hunsaker
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Aldo A. Mendez
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Gustavo Cortez
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Jason M. Davies
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Sandra Narayanan
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - C. Michael Cawley
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Howard A. Riina
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Justin M. Moore
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Alejandro M. Spiotta
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Alexander A. Khalessi
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Brian M. Howard
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Ricardo Hanel
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Omar Tanweer
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Elad I. Levy
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Ramesh Grandhi
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Michael J. Lang
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Adnan H. Siddiqui
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Peter Kan
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Christopher S. Ogilvy
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Bradley A. Gross
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Ajith J. Thomas
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Brian T. Jankowitz
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| | - Jan-Karl Burkhardt
- From the Department of Neurosurgery, Hospital of the University of
Pennsylvania, Penn Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104
(M.M.S., B.T.J., J.K.B.); Department of Neurosurgery, University of Pittsburgh,
Pittsburgh, Pa (O.K., A.A.M., S.N., M.J.L., B.A.G.); Department of Neurosurgery,
Baylor College of Medicine, Houston, Tex (A.N.H., O.T., P.K.); Department of
Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at
Buffalo, Buffalo, NY (A.A.B., J.M.D., E.I.L., A.H.S.); Division of Neurosurgery,
Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, Mass
(M.K., J.M.M., C.S.O., A.J.T.); Department of Neurosurgery, University of Utah,
Salt Lake City, Utah (C.B., J.C.H., R.G.); Department of Cerebrovascular and
Endovascular Surgery, Baptist Neurologic Institute and Lyerly Neurosurgery,
Jacksonville, Fla (G.C., R.H.); Department of Neurosurgery, Emory University
School of Medicine, Atlanta, Ga (C.M.C., B.M.H.); Department of Neurosurgery,
NYU Langone Medical Center, New York, NY (H.A.R.); Department of Neurosurgery,
Medical University of South Carolina, Charleston, SC (A.M.S.); Department of
Neurosurgery, University of California–San Diego, La Jolla, Calif
(A.A.K.); Department of Neurosurgery, University of Texas Medical Branch,
Galveston, Tex (P.K.); and Department of Neurosurgery, Cooper University Health
Care, Cooper Medical School of Rowan University, Camden, NJ (A.J.T.)
| |
Collapse
|
35
|
Krothapalli N, Patel S, Fayad M, Elmashad A, Killory B, Bruno C, Sussman E, Alberts M, Ollenschleger M, Kureshi I, Mehta T. Outcomes of Particle versus Liquid Embolic Materials Used in Middle Meningeal Artery Embolization for the Treatment of Chronic Subdural Hematoma. World Neurosurg 2023; 173:e27-e36. [PMID: 36706981 DOI: 10.1016/j.wneu.2023.01.077] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2023] [Accepted: 01/18/2023] [Indexed: 01/25/2023]
Abstract
BACKGROUND Early evidence suggests that middle meningeal artery (MMA) embolization is an efficacious minimally invasive neuroendovascular technique for the management of chronic subdural hematoma (cSDH). Particle and liquid embolic materials are commonly used to embolize the MMA; however, studies comparing the safety and outcomes between these 2 materials are limited. METHODS Patients ≥18 years old who had MMA embolization for cSDH between July 15, 2020 and May 1, 2022 were retrospectively identified from a single-center database. The primary safety, radiation dosage, fluoroscopy time, and radiographic and clinical outcomes were compared between particle and liquid embolization. RESULTS In a cohort of 116, 48 (41.38%) were treated with liquid embolic material and 68 (58.62%) were treated with particle. The median age of the cohort was 73 years in the particle group and 73.5 years in the liquid embolic group. There was no significant difference in radiation dose or duration among both groups. There was no reported mortality associated with the procedure. One patient experienced nondisabling ischemic stroke in the particle group. Based on imaging follow-up, 3 patients in the particle group and 1 in the liquid embolic group had asymptomatic recurrence. One patient in each group had symptomatic recurrence requiring hematoma evacuation. The index median size of hematoma was 12 mm in the particle group and 11 mm in the liquid embolic group. At approximately 1 month follow-up, the median size of hematoma reduced to 6 mm in both groups. CONCLUSIONS Our series shows that liquid embolic and particle embolization are equally safe and effective among patients undergoing MMA embolization for management of cSDH.
Collapse
Affiliation(s)
- Neeharika Krothapalli
- Department of Neurology, University of Connecticut, Farmington, Connecticut, USA; Ayer Neuroscience Institute, Hartford, Connecticut, USA
| | - Smit Patel
- Ayer Neuroscience Institute, Hartford, Connecticut, USA; Department of Interventional Neuroradiology, Hartford Hospital, Hartford, Connecticut, USA
| | - Mohamad Fayad
- Ayer Neuroscience Institute, Hartford, Connecticut, USA; Department of Interventional Neuroradiology, Hartford Hospital, Hartford, Connecticut, USA
| | - Ahmed Elmashad
- Department of Neurology, University of Connecticut, Farmington, Connecticut, USA; Ayer Neuroscience Institute, Hartford, Connecticut, USA
| | - Brendan Killory
- Ayer Neuroscience Institute, Hartford, Connecticut, USA; Department of Neurosurgery, Hartford Hospital, Hartford, Connecticut, USA
| | - Charles Bruno
- Ayer Neuroscience Institute, Hartford, Connecticut, USA; Department of Interventional Neuroradiology, Hartford Hospital, Hartford, Connecticut, USA
| | - Eric Sussman
- Ayer Neuroscience Institute, Hartford, Connecticut, USA; Department of Neurosurgery, Hartford Hospital, Hartford, Connecticut, USA
| | - Mark Alberts
- Ayer Neuroscience Institute, Hartford, Connecticut, USA; Department of Neurology, Hartford Hospital, Hartford, Connecticut, USA
| | - Martin Ollenschleger
- Ayer Neuroscience Institute, Hartford, Connecticut, USA; Department of Interventional Neuroradiology, Hartford Hospital, Hartford, Connecticut, USA
| | - Inam Kureshi
- Ayer Neuroscience Institute, Hartford, Connecticut, USA; Department of Neurosurgery, Hartford Hospital, Hartford, Connecticut, USA
| | - Tapan Mehta
- Ayer Neuroscience Institute, Hartford, Connecticut, USA; Department of Interventional Neuroradiology, Hartford Hospital, Hartford, Connecticut, USA.
| |
Collapse
|
36
|
de Paula MVCT, Ribeiro BDC, Melo MM, de Freitas PVV, Pahl FH, de Oliveira MF, Rotta JM. Effect of postoperative tranexamic acid on recurrence rate and complications in chronic subdural hematomas patients: preliminary results of a randomized controlled clinical trial. Neurosurg Rev 2023; 46:90. [PMID: 37071217 PMCID: PMC10111300 DOI: 10.1007/s10143-023-01991-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 03/08/2023] [Accepted: 04/06/2023] [Indexed: 04/19/2023]
Abstract
Chronic subdural hematoma (CSDH) is a frequent neurosurgical disease which mainly affects elderly patients. Tranexamic acid (TXA) has been hypothesized as an oral agent to avoid CSDH progression and/or recurrence. We performed an evaluation to determine whether the postoperative use of TXA reduces recurrence rate. A prospective, randomized, and controlled trial. Patients with unilateral or bilateral chronic subdural hematoma undergoing surgical treatment by burr-hole were randomized as to whether or not to use TXA in the postoperative period. We evaluated image and clinical recurrence of CSDH at follow up of 6 months and potential clinical and/or surgical complications impact of TXA. Twenty-six patients were randomized to the control group (52%) and twenty-four patients to the TXA group (48%). Follow-up ranged from 3 to 16 months. There were no significant difference between baseline data in groups regarding to age, gender, use of antiplatelet or anticoagulants, smoking, alcoholism, systemic arterial hypertension, diabetes mellitus, hematoma laterality, hematoma thickness, and drain use. Clinical and radiological recurrence occurred in three patients (6%), being two cases in TXA group (8.3%) and 1 in control group (3.8%). Postoperative complications occurred in two patients during follow-up (4%), being both cases in TXA group (8.3%), and none in the control group. Although TXA group had a higher recurrence rate (8.3%), there was no statistically significant difference between the two groups. Moreover, TXA group had two complications while control group had no complications. Although limited by experimental nature of study and small sample, our current data suggest that TXA should not be used as a potential agent to avoid recurrences of CSDH and might increase complication odds.
Collapse
Affiliation(s)
- Marcus Vinícius Carneiro Torres de Paula
- Department of Neurosurgery, Hospital do Servidor Público Estadual de São Paulo, IAMSPE, Rua Pedro de Toledo, 1800, Vila Clementino, São Paulo, 04029-000, Brazil
| | - Bernardo Duarte Chamon Ribeiro
- Department of Neurosurgery, Hospital do Servidor Público Estadual de São Paulo, IAMSPE, Rua Pedro de Toledo, 1800, Vila Clementino, São Paulo, 04029-000, Brazil
| | - Marina Mendes Melo
- Department of Neurosurgery, Hospital do Servidor Público Estadual de São Paulo, IAMSPE, Rua Pedro de Toledo, 1800, Vila Clementino, São Paulo, 04029-000, Brazil
| | - Pedro Victor Vidal de Freitas
- Department of Neurosurgery, Hospital do Servidor Público Estadual de São Paulo, IAMSPE, Rua Pedro de Toledo, 1800, Vila Clementino, São Paulo, 04029-000, Brazil
| | - Felix Hendrik Pahl
- Department of Neurosurgery, Hospital do Servidor Público Estadual de São Paulo, IAMSPE, Rua Pedro de Toledo, 1800, Vila Clementino, São Paulo, 04029-000, Brazil
| | - Matheus Fernandes de Oliveira
- Department of Neurosurgery, Hospital do Servidor Público Estadual de São Paulo, IAMSPE, Rua Pedro de Toledo, 1800, Vila Clementino, São Paulo, 04029-000, Brazil.
| | - José Marcus Rotta
- Department of Neurosurgery, Hospital do Servidor Público Estadual de São Paulo, IAMSPE, Rua Pedro de Toledo, 1800, Vila Clementino, São Paulo, 04029-000, Brazil
| |
Collapse
|
37
|
Desir LL, Narayan V, Ellis J, Gordon D, Langer D, Ortiz R, Serulle Y. Middle Meningeal Artery Embolization in the Management of Chronic Subdural Hematoma: a Comprehensive Review of Current Literature. Curr Neurol Neurosci Rep 2023; 23:109-119. [PMID: 37037979 DOI: 10.1007/s11910-023-01262-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/20/2023] [Indexed: 04/12/2023]
Abstract
PURPOSE OF REVIEW Chronic subdural hematoma (cSDH) is a common intracranial hemorrhagic disorder with a high incidence rate among the elderly. While small, asymptomatic cSDH may resolve spontaneously, surgical intervention has been the treatment of choice for larger, symptomatic cases. Surgical evacuation of cSDH may be associated with high rates of recurrence, and even asymptomatic cSDH cases tend to progress. Over the last few years, middle meningeal artery (MMA) embolization has proven to be a safe non-invasive treatment of choice with favorable outcomes and a low recurrence rate. The ensuing paper discusses current treatment modalities for cSDH and reviews existing literature on the anatomy of MMA and its embolization as a treatment option for cSDH. RECENT FINDINGS Recent studies show that traumatic head injury leading to subdural hemorrhage can induce neovascularization that may initiate a cycle of recurrent subdural hematoma. Distal branches of MMA supply blood to the dural layers. Several studies have revealed that embolization of the MMA can stop the neovascularization process and blood flow. In addition, patients who underwent MMA embolization had a significantly quicker brain re-expansion and lower recurrence rate. Although the management of cSDH is still very much a dilemma, recent research findings bring MMA embolization to light as a promising treatment alternative and adjunctive therapy.
Collapse
Affiliation(s)
- Likowsky L Desir
- Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA
- City University of New York School of Medicine, New York, NY, USA
| | - Vinayak Narayan
- Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA
| | - Jason Ellis
- Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA
| | - David Gordon
- Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA
| | - David Langer
- Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA
| | - Rafael Ortiz
- Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA
| | - Yafell Serulle
- Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA.
- Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
- Neuroendovascular Surgery, Phelps Hospital, Sleepy Hollow, NY, USA.
| |
Collapse
|
38
|
Saal-Zapata G, Murga-Villanueva A, Walker M, Ghodke B, Rodríguez-Varela R. Safety and radiologic clearance of chronic subdural hematoma after endovascular embolization using SQUID 18 in patients older than 80 years. J Neurosci Rural Pract 2023; 14:336-341. [PMID: 37181175 PMCID: PMC10174137 DOI: 10.25259/jnrp_30_2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2022] [Accepted: 01/15/2023] [Indexed: 02/25/2023] Open
Abstract
The aim of the study was to evaluate radiographic clearance and clinical outcomes in patients over age 80 who undergo SQUID 18 embolization of the middle meningeal artery (MMA) for the management of chronic subdural hematoma (cSDH). From April 2020 to October 2021, data were obtained from patients with cSDH who underwent MMA embolization at our institution. Clinical and radiological data including pre-operative and last follow-up CT scans were analyzed. Six embolization procedures were performed in five patients using SQUID 18, a liquid embolic agent. The median age was 83 years, and three subjects were female. Two of the six cases were recurrent hematomas. MMA embolization was achieved in 100% of cases. The median diameter of the hematoma at admission was 20 mm and at last follow-up was 5.3 mm, demonstrating statistically significant radiographic clearance (P = 0.043). There were no intra or post-operative complications. Mortality was not noted during observation period. SQUID MMA embolization safely and significantly reduced the hematoma diameter and offers an alternative treatment in patients older than 80 years with cSDH.
Collapse
Affiliation(s)
- Giancarlo Saal-Zapata
- Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, United States
| | - Annel Murga-Villanueva
- Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, United States
| | - Melanie Walker
- Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, United States
| | - Basavaraj Ghodke
- Department of Neurological Surgery, University of Washington, Seattle, Washington, United States
| | - Rodolfo Rodríguez-Varela
- Department of Neurosurgery, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, United States
| |
Collapse
|
39
|
Hegde P, Nayak B, Madishetty A, Perikal PJ, Furtado SV. Validating the Efficacy of Two Burr-Hole Craniostomy over Mini-Craniotomy for Chronic Subdural Hematoma Drainage. Asian J Neurosurg 2023; 18:70-74. [PMID: 37056871 PMCID: PMC10089736 DOI: 10.1055/s-0043-1761232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023] Open
Abstract
Abstract
Background There is an increasing incidence of chronic subdural hematoma due to extended life expectancy and associated trauma and fall risk. This retrospective study evaluates the efficacy of two burr-hole craniotomy over mini-craniotomy.
Methods Sixty-five patients were recruited over 2 years, of which 56 were male and 9 were females. A patient with a chronic subdural hematoma either underwent burr-hole craniostomy or mini-craniotomy for hematoma evacuation. Glasgow coma scale (GCS) and modified Rankin score were used to assess the neurological status and interventional outcome at discharge and follow-up, respectively. A head CT scan was performed at 3 week and 3 month follow-up.
Statistical Analysis Categorical data are presented as frequency and percentage, while non-categorical data are represented as mean ± SD. Statistical significance for difference in outcome between the two groups was analyzed using the chi-square test and p-value less than 0.05 was considered statistically significant.
Results The mean age of patients was 55.6 years. Headache (35 cases), hemiparesis, and altered sensorium were seen in 20 patients, each with the main presenting symptoms. Trauma history was noted in 69.2% of patients. One (3.7%) hematoma recurrence in the burr-hole group and four (8.3%) in the mini-craniotomy group was recorded. The mean operative time was longer in the minicraniotomy group (124.2 min vs. 75.4 min; p < 0.001). A higher incidence of recurrence was noted in the craniotomy group (8.3%) than the burr-hole group (3.7%). No statistical difference in the recurrence rate, duration of hospital stay, GCS at discharge, modified Rankin score between the two study groups at discharge was noted.
Conclusion Two burr-hole craniostomy is a safe and effective surgical option to treat chronic subdural hematoma. It is also validated in patients on anticoagulants and antiplatelet medications with adequate pre-surgical correction of coagulation parameters.
Collapse
|
40
|
Gender-Specific Differences in Chronic Subdural Hematoma. J Craniofac Surg 2023; 34:e124-e128. [PMID: 36857560 DOI: 10.1097/scs.0000000000008855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 06/06/2022] [Indexed: 03/02/2023] Open
Abstract
OBJECTIVE Few studies concerning aspects of gender-specific differences in chronic subdural hematoma (CSDH). This study aimed to determine whether gender-specific differences exist in CSDH regarding clinical, radiological characteristics, and prognosis. METHODS A total of 585 patients with CSDH were retrospectively identified. Patients were divided into 2 groups based on gender. Clinical, radiological characteristics, and prognosis were compared using Fisher's exact test or Student t test when applicable. The logistic regression model was used to identify independent risk factors associated with death in CSDH patients. The receiver operating characteristic curve was used to detect the sensitivity and specificity of independent risk factors. RESULTS The average age of women was 71.50±0.92 years, significantly older than 67.30±0.60 years in men. Hypertension, diabetes mellitus, and uremia were significantly more common in women than in men. Alcohol intake was more in males than in females. CSDH patients in males manifested homogeneous iso-dense and homogeneous hyper-dense was obviously more than that in the females. Although homogeneous hypo-dense and mixed density were significantly more common in the females. The average preoperative hematoma volume of the unilateral CSDH in males was 160.85±3.06 cm3, significantly more than 139.60±5.70 cm3 in females. The mortality of females was 7.4%, higher than 1.7% in males (P=0.004). Female, age, uremia, and recurrence were independent risk factors for death in CSDH patients. CONCLUSIONS Gender-specific differences do exist in CSDH. Female, age, uremia, and recurrence were independent risk factors for death in CSDH patients.
Collapse
|
41
|
Rutledge C, Baranoski JF, Catapano JS, Jadhav AP, Albuquerque FC, Ducruet AF. Republished: Resolution of an enlarging subdural haematoma after contralateral middle meningeal artery embolisation. J Neurointerv Surg 2023; 15:e2. [PMID: 33986110 DOI: 10.1136/neurintsurg-2021-017530.rep] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 04/07/2021] [Accepted: 04/08/2021] [Indexed: 11/04/2022]
Abstract
A man in his 50s presented 1 month after an automobile accident with worsening headaches and an enlarging chronic left subdural haematoma (SDH). He underwent left middle meningeal artery (MMA) embolisation. Due to tortuosity at its origin, we were unable to catheterise the MMA distally. Only proximal coil occlusion at the origin was performed. Follow-up interval head CT showed an increase in the size of the SDH with new haemorrhage, worsening mass effect and midline shift. However, he remained neurologically intact. Contralateral embolisation of the right MMA was performed with a liquid embolic agent. His headaches improved, and a follow-up head CT 3 months later showed near-complete resolution of the SDH.
Collapse
Affiliation(s)
- Caleb Rutledge
- Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Jacob F Baranoski
- Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Joshua S Catapano
- Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Ashutosh P Jadhav
- Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Felipe C Albuquerque
- Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| | - Andrew F Ducruet
- Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
| |
Collapse
|
42
|
Shotar E, Barberis E, Chougar L, Bensoussan S, Parat D, Ghannouchi H, Premat K, Lenck S, Degos V, Lehericy S, Sourour NA, Mathon B, Clarençon F. Long-Term Middle Meningeal Artery Caliber Reduction Following Trisacryl Gelatine Microsphere Embolization for the Treatment of Chronic Subdural Hematoma. Clin Neuroradiol 2023; 33:113-120. [PMID: 35796853 DOI: 10.1007/s00062-022-01189-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 06/13/2022] [Indexed: 11/03/2022]
Abstract
PURPOSE Middle meningeal artery (MMA) particle embolization is a promising treatment of chronic subdural hematomas (CSDH). The main purpose of this study is to measure MMA proximal caliber and assess the visibility of the two main MMA branches as a surrogate for long-term distal arterial patency following MMA CSDH embolization with trisacryl gelatine microspheres (TAGM). METHODS This is a single-center retrospective study. All patients having undergone MMA TAGM only embolization for CSDH treatment between 15 March 2018 and 6 June 2020 with an interpretable follow-up magnetic resonance imaging (MRI) examination and no confounding factors were included. Patients were compared with controls matched for age, sex and MRI machine. Two independent readers analyzed the MRI images. RESULTS In this study, 30 patients having undergone embolization procedures using TAGM of 36 MMAs were included. The follow-up MRI scans were performed after a mean delay of 14.8 ± 7.1 months (range 4.9-29.4 months). The mean diameter of TAGM embolized MMAs (1 mm; 95% confidence interval, CI 0.9-1.1) was significantly smaller than the mean diameter of paired control MMAs (1.3 mm; 95% CI 1.3-1.4) (p < 0.001). The mean proximal diameter of the embolized MMAs (0.9 mm; 95% CI 0.7-1.1) was significantly smaller than the mean diameter of the contralateral MMAs in the same patients (1.4 mm; 95% CI 1.3-1.6)(p < 0.001). CONCLUSION Long-term follow-up MRI demonstrated a significant impact of TAGM embolization on MMA proximal caliber as well as on the visibility of the two main MMA branches. All comparisons indicated that there was a probable lasting impact of embolization on the patency of distal branches.
Collapse
Affiliation(s)
- Eimad Shotar
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France.
| | - Eric Barberis
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France
| | - Lydia Chougar
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France.,Sorbonne Université, Paris, France
| | - Sacha Bensoussan
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France
| | - Damien Parat
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France
| | - Haroun Ghannouchi
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France
| | - Kevin Premat
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France
| | - Stephanie Lenck
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France
| | - Vincent Degos
- Sorbonne Université, Paris, France.,Department of Neurosurgical Anesthesiology and Critical Care, Pitié-Salpêtrière Hospital, Paris, France
| | - Stéphane Lehericy
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France.,Sorbonne Université, Paris, France
| | - Nader-Antoine Sourour
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France
| | - Bertrand Mathon
- Sorbonne Université, Paris, France.,Department of Neurosurgery, Pitié-Salpêtrière Hospital, Paris, France
| | - Frédéric Clarençon
- Department of Neuroradiology, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France.,Sorbonne Université, Paris, France
| |
Collapse
|
43
|
Ku JC, Dmytriw AA, Essibayi MA, Banihashemi MA, Vranic JE, Ghozy S, Altschul D, Regenhardt RW, Stapleton CJ, Yang VXD, Patel AB. Embolic Agent Choice in Middle Meningeal Artery Embolization as Primary or Adjunct Treatment for Chronic Subdural Hematoma: A Systematic Review and Meta-analysis. AJNR Am J Neuroradiol 2023; 44:297-302. [PMID: 36797028 PMCID: PMC10187811 DOI: 10.3174/ajnr.a7796] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Accepted: 01/24/2023] [Indexed: 02/18/2023]
Abstract
BACKGROUND Middle meningeal artery embolization is an emerging treatment option for chronic subdural hematomas. PURPOSE Our aim was to assess outcomes following middle meningeal artery embolization by different techniques, including in comparison with traditional surgical methods. DATA SOURCES We searched the literature databases from inception to March 2022. DATA SELECTION We selected studies reporting outcomes after middle meningeal artery embolization as a primary or adjunctive treatment for chronic subdural hematoma. DATA ANALYSIS We analyzed the risk of recurrence of chronic subdural hematoma, reoperation for recurrence or residual hematoma, complications, and radiologic and clinical outcomes using random effects modeling. Additional analyses were performed on the basis of whether middle meningeal artery embolization was used as the primary or adjunct treatment and by embolic agent type. DATA SYNTHESIS Twenty-two studies were included with 382 patients with middle meningeal artery embolization and 1373 surgical patients. The rate of subdural hematoma recurrence was 4.1%. Fifty (4.2%) patients underwent a reoperation for a recurrent or residual subdural hematoma. Thirty-six (2.6%) experienced postoperative complications. The rates of good radiologic and clinical outcomes were 83.1% and 73.3%, respectively. Middle meningeal artery embolization was significantly associated with decreased odds of subdural hematoma reoperation (OR = 0.48; 95% CI, 23.4-99.1; P = .047) compared with surgery. The lowest rates of subdural hematoma radiologic recurrence, reoperation, and complications were observed among patients receiving embolization with Onyx, whereas good overall clinical outcome occurred most commonly with combined polyvinyl alcohol and coils. LIMITATIONS A limitation was the retrospective design of studies included. CONCLUSIONS Middle meningeal artery embolization is safe and effective, either as a primary or adjunctive treatment. Treatment using Onyx seems to yield lower rates of recurrence, rescue operation, and complications whereas particles and coils produce good overall clinical outcomes.
Collapse
Affiliation(s)
- J C Ku
- From the Division of Neurosurgery (J.C.K.)
| | - A A Dmytriw
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- Neurointerventional Program (A.A.D., V.X.D.Y.), Department of Clinical Neurological Sciences & Medical Imaging, Schulich School of Medicine, Western University, London, Ontario, Canada
| | - M A Essibayi
- Departments of Radiology (M.A.E., S.G.), Mayo Clinic, Rochester, Minnesota
- Department of Neurosurgery (M.A.E., D.A.), Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York
| | - M A Banihashemi
- Department of Surgery and Institute of Medical Science (M.A.B.), University of Toronto, Toronto, Ontario, Canada
| | - J E Vranic
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - S Ghozy
- Departments of Radiology (M.A.E., S.G.), Mayo Clinic, Rochester, Minnesota
- Nuffield Department of Primary Care Health Sciences and Department for Continuing Education (EBHC program) (S.G.), Oxford University, Oxford, UK
| | - D Altschul
- Department of Neurosurgery (M.A.E., D.A.), Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York
| | - R W Regenhardt
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - C J Stapleton
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - V X D Yang
- Neurointerventional Program (A.A.D., V.X.D.Y.), Department of Clinical Neurological Sciences & Medical Imaging, Schulich School of Medicine, Western University, London, Ontario, Canada
| | - A B Patel
- Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
44
|
Atefi N, Alcock S, Silvaggio JA, Shankar J. Clinical Outcome and Recurrence Risk of Chronic Subdural Hematoma After Surgical Drainage. Cureus 2023; 15:e35525. [PMID: 37007398 PMCID: PMC10054842 DOI: 10.7759/cureus.35525] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/27/2023] [Indexed: 03/03/2023] Open
Abstract
Introduction Chronic subdural hematoma (CSDH) is one of the most encountered neurosurgical cases. CSDH is defined as the accumulation of liquified blood products in the space between the dura and the arachnoid. A reported incidence of 17.6/100,000/year has more than doubled in the past 25 years in parallel with an aging population. Surgical drainage remains the mainstay of treatment, yet it is challenged by variable recurrence risks. Less invasive embolization methods of the middle meningeal artery (EMMA) could reduce the recurrence risks. Before adopting a newer treatment (EMMA), it is prudent to establish the outcomes from surgical drainage. The purpose of this study is to assess the clinical outcome and recurrence risk in surgically treated CSDH patients in our center. Methods A retrospective search of our surgical database was done to identify CSDH patients undergoing surgical drainage in the year 2019-2020. Demographic and clinical details were collected, and quantitative statistical analysis was performed. Peri-procedural radiographic information and follow-ups were also included as per the standard of care. Results A total of 102 patients (mean age: 69 years; range: 21-100 years; male: 79) with CSDH underwent surgical drainage with repeat surgery in 13.7% of the patients (n=14). Peri-procedural mortality and morbidity were 11.8%(n=12) and 19.6% (n=20), respectively. Overall, among our patient population, recurrence was seen in 22.55% (n=23). The mean total hospital stay was 10.6 days. Conclusions Our retrospective cohort study showed an institutional CSDH recurrence risk of 22.55%, in keeping with what is reported in the literature. This baseline information is important for a Canadian setting and provides a basis for comparison for future Canadian trials.
Collapse
|
45
|
Lin MS. Subdural Lesions Linking Additional Intracranial Spaces and Chronic Subdural Hematomas: A Narrative Review with Mutual Correlation and Possible Mechanisms behind High Recurrence. Diagnostics (Basel) 2023; 13:diagnostics13020235. [PMID: 36673045 PMCID: PMC9857428 DOI: 10.3390/diagnostics13020235] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2022] [Revised: 12/11/2022] [Accepted: 01/05/2023] [Indexed: 01/10/2023] Open
Abstract
The purpose of this study was two-fold. The first was to investigate the pathologic mechanisms underlying the formation of subdural fluid collection, an umbrella term referring to a condition commonly seen in the clinical setting. Accumulation of the cerebrospinal fluid (CSF) in the subdural space can be referred to in this disease category, disregarding the underlying source of the subdural fluid. However, in these two clinical situations, especially after trauma or brain surgery, fluid collection from the subarachnoid space (subdural hygroma) or from the ventricle to the subarachnoid space and infusion into the subdural space (external hydrocephalus), surgical management of critical patients may adopt the strategies of burr-hole, subduroperitoneal shunt, or ventriculoperitoneal shunt, which present distinctly different thoughts. Crucially, the former can be further transformed into chronic subdural hematoma (CSDH). The second significant theme was the pathogenesis of CSDH. Once the potential dural border cell (DBC) layer is separated such as if a wound is formed, the physiological mechanisms that seem to promote wound healing will resume in the subdural space as follows: coagulation, inflammation, fibroblast proliferation, neovascularization, and fibrinolysis. These aptly correspond to several key characteristics of CSDH formation such as the presence of both coagulation and fibrinolysis signals within the clot, neomembrane formation, angiogenesis, and recurrent bleeding, which contribute to CSDH failing to coagulate and absorb easily. Such a complexity of genesis and the possibility of arising from multiple pathological patterns provide a reasonable explanation for the high recurrence rate, even after surgery. Among the various complex and clinically challenging subdural lesions, namely, CSDH (confined to the subdural space alone), subdural hygroma (linked in two spaces), and external hydrocephalus (linked in three spaces), the ability to fully understand the different pathological mechanisms of each, differentiate them clinically, and devote more interventional strategies (including anti-inflammatory, anti-angiogenic, and anti-fibrinolysis) will be important themes in the future.
Collapse
Affiliation(s)
- Muh-Shi Lin
- Division of Neurosurgery, Department of Surgery, Kuang Tien General Hospital, Taichung 43303, Taiwan; ; Tel.: +886-4-2665-1900
- Department of Biotechnology and Animal Science, College of Bioresources, National Ilan University, Yilan 26047, Taiwan
- Department of Biotechnology, College of Medical and Health Care, Hung Kuang University, Taichung 43302, Taiwan
- Department of Health Business Administration, College of Medical and Health Care, Hung Kuang University, Taichung 43302, Taiwan
| |
Collapse
|
46
|
Msheik A, Fares Y, Mohanna M, Aoude A, Shkeir M, Chehade F, Kanj A, Mohanna A. Middle meningeal artery embolisation: The review of a new treatment for chronic subdural hematomas. Surg Neurol Int 2023; 14:66. [PMID: 36895214 PMCID: PMC9990792 DOI: 10.25259/sni_1096_2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 02/03/2023] [Indexed: 02/26/2023] Open
Abstract
Background This is a literature review aiming to provide an update about the recent findings related to the efficacy of middle meningeal artery embolization (MMAE) in the treatment of chronic subdural hematomas (cSDHs), comparison with conventional therapy and deduction of the current recommendations and indications. Methods The literature is reviewed using a search through the PubMed index using keywords. Studies are then screened, skimmed, and thoroughly read. 32 studies fulfilled the inclusion criteria and are included in the study. Results Five indications for the application of MMA embolization (MMAE) are deducted from the literature. The usage as a preventive measure after surgical treatment of symptomatic cSDHs in patients with a high risk of recurrence and the usage as a standalone procedure has been the most common reasons for indication of this procedure. Rates of failures for the aforementioned indications have been 6.8% and 3.8%, respectively. Conclusion The safety of MMAE as a procedure is regarded as a general theme in the literature and can be considered for future applications. Usage of this procedure in clinical trials with more patient segregation and timeframe assessment relative to surgical intervention are recommendations of this literature review.
Collapse
Affiliation(s)
- Ali Msheik
- Department of Neurological Surgery, Lebanese University, Faculty of Medical Sciences
| | - Youssef Fares
- Department of Neurological Surgery, Neuroscience Research Center, Faculty of Medical Sciences, Lebanese University, Lebanon
| | - Mohammad Mohanna
- Department of Oncology, Cleveland Clinic, Weston, Florida, United States
| | - Ahmad Aoude
- Department of Neurological Surgery, Al Rassoul Al-Azam Hospital
| | - Mohamad Shkeir
- Head of Radiology Department, Zahraa Hospital University Medical Center
| | - Feras Chehade
- Department of Nuclear Medicine Radiobiology Radiopathology, Faculty of Medical Sciences, Lebanese University
| | - Ali Kanj
- Radiology Department, Bahman Hospital, Faculty of Medicine, Lebanese University
| | - Assaad Mohanna
- Head of Department of Radiology, Faculty of Medicine, Lebanese University, Bahman Hospital, Centre Hospitalier Vallee de la Maurienne-France, Beirut, Lebanon
| |
Collapse
|
47
|
Fuentes AM, Khalid SI, Mehta AI. Predictors of Subsequent Intervention After Middle Meningeal Artery Embolization for Treatment of Subdural Hematoma: A Nationwide Analysis. Neurosurgery 2023; 92:144-149. [PMID: 36129273 DOI: 10.1227/neu.0000000000002151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Accepted: 07/16/2022] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Middle meningeal artery (MMA) embolization has recently emerged as an effective technique to treat subdural hematomas (SDHs). Studies to date have been limited, largely, to single-center studies with limited follow-up and have not assessed subsequent surgical interventions and factors associated with these interventions. OBJECTIVE To evaluate rates of retreatment for SDH after MMA embolization and patient-specific factors that may be important predictors for these interventions. METHODS Using an all-payer claims database, Mariner, patients who underwent MMA embolization between January 2010 and October 2020 after the diagnosis of SDH were identified. Rates of post-MMA embolization surgical interventions, including craniotomy and burr hole drainage, were accessed within 5 years following. Patient-specific contributors to the rates of these interventions were studied using Gaussian logistic regression models. RESULTS A total of 322 patients were included. Of this cohort, 55 (17.1%) required subsequent intervention within 5 years, with 36 (11.2%) receiving burr hole evacuation and 19 (5.9%) receiving craniotomy. Factor Xa inhibitor use was independently associated with subsequent interventions after MMA embolization procedures (odds ratio: 1.20 [95% CI: 1.02-1.40]). Of the other patient factors evaluated, including age, sex, comorbidity status, and use of vitamin K antagonists, antiplatelets, and factor Xa inhibitors, none were found to be significantly associated with future interventions. CONCLUSION Although previous literature has shown MMA embolization to be safe and successful in preventing recurrent SDH, patients undergoing this procedure still carry a risk of future interventions. Patients taking factor Xa inhibitors are at especially high risk of subsequent intervention after MMA embolization.
Collapse
Affiliation(s)
- Angelica M Fuentes
- Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois, USA
| | | | | |
Collapse
|
48
|
Pedicelli A, Valente I, Alexandre A, Scarcia L, Gigli R, Signorelli F, Visocchi M. Middle Meningeal Artery Embolization for the Management of Chronic Subdural Hematomas: A New-Old Treatment. ACTA NEUROCHIRURGICA. SUPPLEMENT 2023; 135:115-118. [PMID: 38153458 DOI: 10.1007/978-3-031-36084-8_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2023]
Abstract
Chronic subdural hematoma (cSDH) is defined as a subdural collection of blood on CT imaging that tends to persist and gradually increase in volume over time, with components that are hypodense or isodense compared to the brain. There are no proven guidelines for the management of patients with cSDH. Surgical approaches included burr hole, twist drill hole, and craniotomy-based evacuations. Outcomes after surgical removal is generally favorable, but cSDH tends to recur after the initial evacuation.Middle meningeal artery (MMA) embolization has been gaining increasing popularity among the treatments of cSDH. This is largely due to a growing population of patients with cSDH who are refractory to other treatments or in patients who present with multiple comorbidities or who are taking antiplatelet and anticoagulant medications. The goal of middle meningeal artery (MMA) embolization is to devascularize subdural membranes associated with SDH so that the balance between continued leakage and reabsorption is shifted toward reabsorption.We discuss our clinical and technical approach to cSDH treated with perioperative embolization of the MMA.
Collapse
Affiliation(s)
- A Pedicelli
- Dipartimento di Diagnostica per immagini, Radioterapia, Oncologia ed Ematologia, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy
| | - I Valente
- Dipartimento di Diagnostica per immagini, Radioterapia, Oncologia ed Ematologia, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy.
| | - A Alexandre
- Dipartimento di Diagnostica per immagini, Radioterapia, Oncologia ed Ematologia, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy
| | - L Scarcia
- Università Cattolica del Sacro Cuore, sede di Roma, Rome, Italy
| | - R Gigli
- Università Cattolica del Sacro Cuore, sede di Roma, Rome, Italy
| | - Francesco Signorelli
- Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Massimiliano Visocchi
- Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Institute of Neurosurgery, Catholic University of Rome, Rome, Italy
| |
Collapse
|
49
|
OTSUJI R, AMANO T, MATSUO S, MIYAMATSU Y, HARA K, TOKUNAGA S, NAKAMIZO A. Chronic Subdural Hematoma after Craniotomy with Preoperative Embolization of Middle Meningeal Artery: A Case Report. NMC Case Rep J 2022; 9:151-155. [PMID: 35836492 PMCID: PMC9239696 DOI: 10.2176/jns-nmc.2022-0007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 03/22/2022] [Indexed: 11/20/2022] Open
Abstract
Endovascular embolization of the middle meningeal artery (MMA) has been reported as an effective method for treating chronic subdural hematoma (CSDH); however, its preventive effect on CSDH following craniotomy is unknown. We present a case in which MMA embolization was ineffective in preventing CSDH following craniotomy. A 56-year-old man who complained of diplopia was diagnosed with sphenoid ridge meningioma with a 3-cm diameter. MMA embolization prior to the operation and total surgical removal of the tumor were performed. Two months postoperatively, the patient complained of headache and hemiparesis of the left side. CSDH with a 15-mm thickness and a midline shift was observed. MMA embolization before inflammation may not play a role in preventing CSDH development because MMA embolization is considered effective in CSDH because it is associated with the blood supply of neovessels that are newly formed due to inflammation. Therefore, MMA embolization might not be effective in preventing the occurrence of CSDH following craniotomy.
Collapse
Affiliation(s)
- Ryosuke OTSUJI
- Department of Neurosurgery, National Hospital Organization Kyushu Medical Center, Clinical Research Institute
| | - Toshiyuki AMANO
- Department of Neurosurgery, National Hospital Organization Kyushu Medical Center, Clinical Research Institute
| | - Satoshi MATSUO
- Department of Neurosurgery, National Hospital Organization Kyushu Medical Center, Clinical Research Institute
| | - Yuichiro MIYAMATSU
- Department of Neurosurgery, National Hospital Organization Kyushu Medical Center, Clinical Research Institute
| | - Kenta HARA
- Department of Neuroendovascular Surgery, National Hospital Organization Kyushu Medical Center, Clinical Research Institute
| | - So TOKUNAGA
- Department of Neuroendovascular Surgery, National Hospital Organization Kyushu Medical Center, Clinical Research Institute
| | - Akira NAKAMIZO
- Department of Neurosurgery, National Hospital Organization Kyushu Medical Center, Clinical Research Institute
| |
Collapse
|
50
|
Shehabeldin M, Amllay A, Jabre R, Chen CJ, Schunemann V, Herial NA, Gooch MR, Mackenzie L, Choe H, Tjoumakaris S, Rosenwasser RH, Jabbour P, Kozak O. Onyx Versus Particles for Middle Meningeal Artery Embolization in Chronic Subdural Hematoma. Neurosurgery 2022; 92:979-985. [PMID: 36700752 DOI: 10.1227/neu.0000000000002307] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Accepted: 10/14/2022] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Middle meningeal artery (MMA) embolization has recently emerged as a treatment option for chronic subdural hematoma (cSDH). It is considered a simple and potentially safe endovascular procedure. OBJECTIVE To compare between 2 different embolic agents; onyx (ethylene vinyl alcohol) and emboparticles (polyvinyl alcohol particles-PVA) for endovascular treatment of cSDH. METHODS A retrospective analysis of all patients who underwent MMA embolization for cSDH treatment in 2 comprehensive centers between August 2018 and December 2021. Primary outcomes were failure of embolization and need for rescue surgical evacuation. RESULTS Among 97 MMA embolizations, 49 (50.5%) received onyx and 48 (49.5%) received PVA. The presence of acute or subacute on cSDH was higher in the PVA group 11/49 (22.5%) vs 30/48 (62.5%), respectively, P < .001. There were no significant differences between both groups regarding failure of embolization 6/49 (12.2%) vs 12/48 (25.0%), respectively, P = .112, and need of unplanned rescue surgical evacuation 5/49 (10.2%) vs 8/48 (16.7%), respectively, P = .354. Hematoma thickness at late follow-up was significantly smaller in the PVA group 7.8 mm vs 4.6 mm, respectively; P = .017. CONCLUSION Both onyx and PVA as embolic agents for cSDH can be used safely and have comparable clinical and surgical outcomes.
Collapse
Affiliation(s)
- Mohamed Shehabeldin
- Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA
| | - Abdelaziz Amllay
- Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA
| | - Roland Jabre
- Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA
| | - Ching-Jen Chen
- Department of Neurosurgery, University of Texas Health Science Center, Houston, Texas, USA
| | - Victoria Schunemann
- Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA.,Department of Neurosurgery, Abington Memorial Hospital, Abington, Pennsylvania, USA
| | - Nabeel A Herial
- Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA
| | - M Reid Gooch
- Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA
| | - Larami Mackenzie
- Neurovascular Division, Abington Memorial Hospital, Jefferson Health, Abington, Pennsylvania, USA
| | - Hana Choe
- Neurovascular Division, Abington Memorial Hospital, Jefferson Health, Abington, Pennsylvania, USA
| | - Stavropoula Tjoumakaris
- Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA
| | - Robert H Rosenwasser
- Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA
| | - Pascal Jabbour
- Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA
| | - Osman Kozak
- Neurovascular Division, Abington Memorial Hospital, Jefferson Health, Abington, Pennsylvania, USA
| |
Collapse
|